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Chronic liver disease encompasses the steady destruction of hepatic tissue over time, resulting in 
the replacement of healthy liver tissue with damaged fibrotic and cirrhotic tissue. Among other 
symptoms, cirrhosis manifests itself with regenerative hepatic nodules and portal hypertension, 
triggering a loss of liver functionality and poor quality of life. Moreover, in the United States, 
cirrhosis remains the 12th leading cause of death, incurring healthcare costs of billions of dollars. 
Despite the astronomical costs and limited palliative care, the only effective treatment for cirrhosis 
is liver transplantation. The demand for liver transplants, however, far exceeds the availability of 
donor livers, underpinning the need for harnessing the liver’s innate regenerative capacity. Using 
zebrafish as a model organism, the main aim of this dissertation is to elucidate the underlying 
mechanisms of liver progenitor cell (LPC)-driven liver regeneration as well as liver development, 
since events involved in the former process can be recapitulated in the latter. Our lab previously 
characterized the biliary epithelial cell (BEC)-driven liver regeneration in which after extensive 
hepatocyte ablation, BECs dedifferentiate into LPCs and subsequently, the LPCs can re-
differentiate into mature hepatocytes/BECs. During this regenerative process, our RNAseq 
analysis showed an upregulation of genes mediating the Bone Morphogenetic Protein (BMP) 
pathway, including a BMP downstream target gene, Inhibitor of DNA binding 2a (Id2a). Using 
loss- and gain-of-function approaches, we show Id2a to be an important regulator of hepatic 
outgrowth during liver development as well as an important mediator of BEC repopulation in LPC-
driven liver regeneration. In addition, as LPC activation is often accompanied by an inflammatory 
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cell response, our second focus was on the role of Signal Transducer and Activator of Transcription 
3 (Stat3) in the LPC-driven liver regeneration model. By chemically inhibiting Stat3, we show 
Stat3 signaling regulates not only the differentiation of LPCs into hepatocytes, but also the 
proliferation of BECs during LPC-driven liver regeneration.  
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1.0  INTRODUCTION 
The liver performs several key regulatory and metabolic functions important for maintaining 
homeostasis, such as: immune regulation, synthesis and secretion of cholesterol, bile and blood 
clotting factors, metabolism of urea and glucose as well as drug detoxification. As blood from the 
intestine has direct contact with the liver, the liver is easily exposed to harmful substances 
throughout an organism’s lifetime. Furthermore, due to the importance of the liver in homeostatic 
processes, any injurious exposure or congenital manifestation can be debilitating to the human 
health. Liver disease can arise from various etiologies, including metabolic, congenital and 
infectious (hemochromatosis, alpha-1 anti-trypsin deficiency, acute hepatitis A, B, E and acute 
HSV hepatitis), leading to severe morbidity and mortality. Considering the importance of the liver 
in homeostatic maintenance, it is not surprising to find the liver possesses the incredible capacity 
to regenerate. In unfolding the process of liver regeneration, it is equally significant to 
simultaneously study the process of liver development. In fact, several signaling pathways and 
genes active during hepatogenesis are also important for liver regeneration. Therefore, using 
zebrafish as a model organism, the primary focus of this dissertation is to understand the 
mechanisms involved in liver development and liver regeneration.  
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1.1 SIGNIFICANCE AND RELEVANCE TO HUMAN HEALTH 
Chronic liver disease and cirrhosis are the 12th leading cause of death in the United States and the 
4th most common among middle-aged adults [1]. Currently in the United States, for the 
approximate 40,000 patients suffering from end-stage chronic liver disease, liver transplantation 
remains the primary, proven and effective therapy. Unfortunately, the increasing demand for 
transplantable livers cannot solely be fulfilled by the available donors, a cohort that continues to 
plunge dramatically: from 7017 in 2006 to 6683 in 2011 [2]. Furthermore, the US health care cost 
associated with advanced liver disease or cirrhosis demands attention: direct costs 
(hospitalization/drug therapies) amount to $2.5 billion and indirect costs (quality of life, work 
productivity) can amount as high as $10.6 billion annually [3]. In addition, patients suffering from 
chronic liver disease are at an increased risk of developing hepatocellular carcinoma, the second 
leading cause of all cancer deaths worldwide [4]. 
Undoubtedly for these patients, there exists a pressing need to fully recognize the 
underlying mechanisms involved in the intricate processes of liver development and regeneration. 
Since processes and mechanisms active during development can often be recapitulated during 
regeneration, it is vital to study both events in unison to address the ultimate goal of liver research: 
identify novel targets that will enhance or restore the liver’s innate regenerative capacity in patients 
suffering from chronic liver diseases.  
 3 
1.2  ZEBRAFISH AS A MODEL ORGANISM 
Originally used as a research model organism in 1937, zebrafish (Danio rerio) are now used 
extensively to study developmental and regenerative processes as well as human diseases, such as 
cancer [5-9]. Specifically, zebrafish are a useful in vivo model for studying liver development and 
disease for several reasons. Zebrafish embryos develop outside of the mother. Embryos are large 
and initially optically transparent, allowing for easy visualization and accessibility during early 
development. Each mating opportunity can produce hundreds of embryos from a single clutch and 
these embryos can develop rapidly with a short generation time from birth to adulthood (about 3 
months). In fact, organ development in zebrafish is relatively rapid: the heart begins beating by 24 
hours post fertilization (hpf) and a functional liver forms by 5 days post fertilization (dpf). The 
zebrafish also have organs relevant for the study of human disease, including eyes, kidneys, heart 
and liver.  
Zebrafish are especially important for small molecule in vivo chemical screening [10]. Due 
to their small size, zebrafish embryos can be efficiently utilized for high throughput assays to 
screen for clinically relevant drugs with therapeutic potential [11, 12]. Previously successful 
screens have included effects of compounds on increasing hematopoietic stem cell numbers [13], 
tumor growth suppressors [14], kidney cyst formation [15] and liver injury [16].  
Many developmental and disease mechanisms as well as signaling pathways observed in 
humans and rodents have been successfully recapitulated in zebrafish [17]. Indeed, although the 
zebrafish teleost group experienced a genome duplication event between 250-400 million years 
ago [18], zebrafish still share about 70% of their genomes with humans and > 80% of disease-
associated genes. The zebrafish genome has been fully sequenced [19]. Due to the maternal 
contribution of mRNA during early development, zebrafish mutants can also bypass the zygotic 
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demand for specific genes during development, allowing for the study of a genetic deficiency at 
later stages. 
Several powerful tools and techniques have been developed to modify zebrafish genetics 
and investigate effects on development and disease. These techniques include generation of 
transgenic fish and forward and reverse genetic approaches. Using the Tol2 transposase system, 
numerous transgenic zebrafish lines have been produced for easy visualization of organs (i.e., liver, 
pancreas, heart), active signaling pathways (i.e., BMP, Notch, Wnt) and genetic injury models [20-
25].  
Forward genetic screening is an unbiased approach in which random mutations are 
introduced into the zebrafish genome following N-ethyl-N-nitrosourea (ENU) mutagenesis or 
retroviral insertion. Subsequent generations of zebrafish mutants of unknown genetic variation are 
analyzed for deleterious phenotype in an organ or gene of interest. Once a phenotype has been 
established, the mutant is further studied to pinpoint the corresponding mutated or defective gene. 
This approach in forward genetics has led to the discovery of several zebrafish mutants with liver-
specific phenotypes [26], including uhrf1 [27], wnt2bb [28] and fgf10 [29].  
Besides forward genetics screening, reverse genetics has also been successfully applied in 
zebrafish. For transient, knockdown studies, morpholino oligonucleotides (MOs) are used to block 
either mature mRNA translation or mRNA splicing of a gene of interest. Typically, MOs are 
injected at the 1-4-cell stage, making them especially powerful for developmental studies [30, 31]. 
Although MOs can provide useful information about effects of temporary gene knockdown, they 
have also been subject to criticism for off-target effects [32]. In addition, zebrafish have been 
targets of knockout (KO) studies. Targeted mutagenesis has come to the forefront in recent years 
with the discovery of Transcription Activator-Like Effector Nuclease (TALEN) and Clustered 
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Regularly Interspaced Short Palindromic Repeats (CRISPR) Type II system [33, 34]. Due to its 
improved knockout efficiency, CRISPR has replaced previous methods of genetic manipulation, 
including TALENs and zinc finger nucleases (ZFNs). Originally adapted from the bacterial 
defense mechanism, CRISPR technology allows for gene manipulation with the design of site-
specific guide RNAs that direct the nonspecific CRISPR-associated endonuclease (Cas9) to the 
genomic site of interest. DNA cleavage by Cas9 endonuclease results in double strand breaks 
(DSB) at the genomic target sequence, which activates the non-homologous end joining (NHEJ) 
repair pathway. NHEJ is an error-prone repair pathway that results in a range of mutations due to 
random insertions or deletions (indels) at the cleaved site.  
1.3 LIVER DEVELOPMENT 
1.3.1 Overview of Liver Structure  
As the largest internal organ in humans, the liver comprises 2-5% of the whole-body weight. The 
mammalian liver is organized into a lobular structure of hexagonal shape with each lobe containing 
bi-layered plates of parenchymal, polarized epithelial cells, termed hepatocytes [see Figure 1]. 
Hepatocytes are the main functional cells of the liver and conduct a multitude of functions, 
including bile and cholesterol synthesis and drug detoxification. At each corner of the hexagonal 
lobule is a portal triad, consisting of a hepatic artery, portal vein and a bile duct. From the intestine, 
blood rich in toxins and nutrients enters the liver at the portal vein; however, since this blood does 
not come directly from the heart, it contains mostly deoxygenated blood. Hence, the hepatic artery 
is necessary for providing an oxygenated blood supply to the liver. Blood then travels towards the 
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center of the lobule, termed the central vein, where it is eventually returned to circulation. 
Surrounding the hepatocytes are fenestrated endothelial cells termed sinusoids. Blood flows 
through the sinusoids from the portal triad towards the central vein.  
Hepatocytes secrete bile into the canaliculi channels located at their apical membrane. Bile 
travels in a reciprocal direction to the blood flow, through the canals of Hering to the bile duct 
located in the portal triad [35, 36]. The bile duct is lined with biliary epithelial cells (BECs or 
cholangiocytes), which are important for bile and fluid secretion. The bile ducts will converge into 
the common hepatic duct, which transports bile from the liver to the gallbladder for storage.  
In addition to hepatocytes, BECs and endothelial cells, additional cell types in the liver 
include hepatic stellate cells (HSCs) and Kupffer cells. HSCs are peri-sinusoidal pericytes found 
in the space of Disse and major contributors to liver fibrosis. Kupffer cells are specialized resident 
macrophages.  
Although many of the hepatic cell types are evolutionarily conserved in zebrafish and 
humans, the zebrafish hepatic architecture is notably different from the human architecture. In 
contrast to the lobular structure, zebrafish liver is organized in a tubular shape with hepatocytes 
arranged in cords surrounding a single biliary channel composed of a single BEC. Bile travels 
from the hepatocytes through the pre-ductular intrahepatic bile channels to the extrahepatic and 
common hepatic duct. Endothelial cells line the basal side of the hepatocytes. Instead of the hepatic 
artery/portal vein present at the edge of the lobule, these structures are interspersed throughout the 
zebrafish liver. Upon injury, HSCs, typically quiescent vitamin A-storing cells, are activated and 
transform into myofibroblast-like cells. Myofibroblast-like cells secrete extracellular matrix 
(ECM) components such as collagen into the hepatic environment, which can be the basis of liver 
fibrosis. HSCs have also been identified in zebrafish and similar to humans and rodents, activated 
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HSCs are important for ECM deposition [37]. No resident macrophages (i.e., Kupffer cells) have 
yet been identified in zebrafish. 
Besides the technical differences, metabolic zonation is also absent in zebrafish. The 
human liver displays functional plasticity, whereby differential gene expression results in 
hepatocyte-specific functional heterogeneity. This plasticity and variation in expression is caused 
by the location of hepatocytes and their proximity to either the portal triad or the central vein [38]. 
Unlike mammals, fetal hematopoiesis and early vasculogenesis do not occur in the zebrafish livers. 
Due to the absence of these two processes, the zebrafish can be used to study genes important in 
hepatogenesis, independent of hematopoiesis-related or early vasculogenesis-related phenotypes 
[39].  
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Figure 1: Overview of the mammalian and zebrafish liver structure 
(A) The mammalian liver is organized into a lobular structure with the portal triads (containing hepatic 
artery, portal vein and bile duct) situated at each corner of the lobule. A zoomed-in view shows that 
while blood flows from the portal vein towards the central vein, bile flows in the opposite direction 
towards the portal triad. In addition to the two epithelial cell types found in the liver (i.e., hepatocytes 
and biliary epithelial cells (BECs)), the liver also contains Kupffer cells, hepatic stellate cells (HSCs) 
and liver sinusoidal endothelial cells. (B) The zebrafish liver is organized into a tubular structure. 
(Left) Confocal image of a 5-dpf liver stained with Alcam (BEC marker) in Tg(fabp10a:CFP-NTR; 
Tp1: H2B-mCherry) transgenic fish highlighting hepatocytes (blue) and BEC nuclei (red). (Right) 
Zoomed-in schematic of zebrafish liver structure with hepatocyte layers (blue) surrounding a single 
BEC (red), which projects its ductule (green). At their apical side, hepatocytes contain bile canaliculi 
(yellow/red outline), while at the basal end, hepatocytes are adjacent to the liver sinusoidal vessels 
(red). The HSCs can be found adjacent at the basal side of the hepatocytes, adjacent to the vessels 
(yellow). Note: Cell size not drawn to scale. 
1.3.2 Overview of Liver Development in Mammals and Zebrafish 
During gastrulation, three primary germ layers are formed: ectoderm, mesoderm and endoderm. 
The endoderm gives rise to several organs, including the stomach, pancreas and liver. The 
definitive endoderm forms when epiblast cells migrate into the cell interior through the primitive 
streak, displacing the visceral endoderm. During organogenesis, the definitive endoderm forms the 
primitive gut tube epithelium adjacent to mesodermal-derived tissue. Along the anterior-posterior 
and dorsal-ventral axes, the gut tube is patterned into 3 different domains: foregut, midgut and 
hindgut. This endodermal patterning is Wnt- and FGF-dependent as Wnt ligands (Wnt8, Wnt8b 
and Wnt3) and FGF4 signals from the adjacent mesoderm promote hindgut formation and suppress 
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foregut identity [40, 41]. Since the liver arises from the ventral/anterior foregut endoderm, Wnt 
signaling must be repressed to allow foregut endoderm formation [40, 42, 43].  
Following endoderm patterning, foregut endodermal cells gain the competence to respond 
to inductive signals from the surrounding mesenchyme mainly due to the expression of specific 
pioneer transcription factors (i.e., FOXA and GATA). Prior to hepatoblast specification, FOXA 
and GATA regulate hepatic competence by occupying regulatory sites on chromatin gene enhancer 
regions, including that of the liver-specific gene, Albumin [44-46]. In the absence of enhancer site 
occupation, chromatin remains compact and Albumin gene transcription does not occur [47]. In 
the liver, FOXA/GATA binding facilitates chromatin accessibility for liver-specific factors.  
Expressed in the foregut endoderm, GATA4, 5 and 6 are zinc finger transcription factors 
regulating endoderm differentiation as well as cardiac development [48-50]. Gata4-/- and Gata6-/- 
single knock-out embryos are embryonic lethal due to an impairment of extraembryonic endoderm 
differentiation and failure of gastrulation [51, 52]. To bypass this defect, Gata6-/- embryos were 
generated from via the tetraploid complementation assay. The embryos were obtained from Gata6-
/- ES cells and wild-type extraembryonic tissues. In these embryos, although endoderm 
specification occurs normally, the liver bud fails to expand [53, 54]. In zebrafish, single 
knockdown of gata4 or 6 also exhibit impaired liver expansion. Interestingly, Gata4/6 double 
knockdowns fail to develop a liver bud altogether. These data suggest the redundant roles of 
Gata4/6 in liver development [55].  
Highly expressed in the liver, FOXA, also known as hepatocyte nuclear factor 3 (HNF3), 
is a transcription factor composed of forkhead DNA-binding motif (i.e., winged helix) as part of 
the helix-turn-helix class of proteins. Similar to the GATA factors, FOXA factors also play 
redundant roles during hepatogenesis. Both FOXA1 and A3 are expressed in the foregut endoderm 
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but FOXA1 or FOXA3 depletion alone appears to have no detrimental effect on liver development 
[56, 57]. Even when FoxA1 or A3 are simultaneously mutated in mice, liver development still 
occurs normally. FoxA2 single-KO mice die prematurely due to aberrant notochord/node 
development [58, 59]. Interestingly, when FoxA1/A2 are both deleted (FoxA2 conditionally from 
the foregut endoderm at embryonic day (E) 8.5), hepatoblast specification is compromised and the 
liver bud fails to form. This highlights that single depletion of FOXA factors has little effect on 
hepatic competence and hepatoblast specification; together, however, FOXA1/A2 regulate the 
early liver developmental process [60].  
Once competent endodermal cells are identified, liver development in zebrafish and 
mammals proceeds in three main stages: (1) hepatoblast specification; (2) hepatoblast 
differentiation; and (3) hepatic outgrowth.  
Hepatoblast specification occurs when signals from the surrounding mesenchyme, such as 
the cardiac mesoderm and the septum transversum mesenchyme (STM), prompt the competent 
endodermal cells to commit to a hepatic fate. At E9.0 following specification, the hepatic 
diverticulum forms and is lined by hepatic endodermal cells at the anterior end. These cells, termed 
hepatoblasts, are a single layer of cuboidal-shaped epithelium that eventually transforms into a 
pseudostratified epithelium. Hepatoblasts proliferate and, together with mesenchymal tissues, 
produce matrix metalloproteinases (MMPs) that aid in degrading the extracellular matrix (ECM) 
in the basal lamina [61]. As the basal layer degrades, hepatoblasts delaminate and migrate into the 
septum transversum mesenchyme (STM). Subsequently, this newly formed liver bud undergoes 
immense growth as hepatoblasts continue to proliferate between E10-15. Also, during this time 
process, between E9.5 to 12.5, the bi-potent progenitor hepatoblasts differentiate into either 
hepatocytes or BECs.  
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In zebrafish, no hepatoblast migration occurs. Instead at 24 hpf, the endoderm-derived 
intestinal rod forms a bar of midline cells. Between 24-28 hpf, the intestinal rod thickens and loops 
as cells at the anterior region aggregate. The cell aggregate begins to bud leftward, away from the 
intestinal rod, forming the liver primordium. In zebrafish, the initiation of hepatoblast specification 
can be detected as early as 22-24 hpf with the onset of hhex and prox1a expression [62, 63]. 
Hepatoblast-to-hepatocyte differentiation can be detected as early as 32 hpf with the ceruloplasmin 
(cp) marker [64] or at 48 hpf with the fatty acid binding protein (fabp10a) [65]. Hepatoblast-to-
biliary differentiation can be detected with the 2F11 or Keratin-18 staining [66, 67]. Following 
differentiation, hepatic outgrowth occurs at 50 hpf and consists of the rapid proliferation of 
hepatocytes and BECs as well as the morphogenesis of the biliary network.   
The next section will examine the signaling pathways and factors important for the three 
stages of liver development.  
1.3.3 Signaling Pathways and Factors Regulating Liver Development 
Liver specification initiates once the ventral foregut endoderm receives inductive signals, 
including fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) from the 
surrounding cardiac mesoderm and STM, respectively [68]. During hepatogenesis, as zebrafish do 
not possess a STM, embryos receive inductive BMP signals from the lateral plate mesoderm 
(LPM). Although FGF signals are also important for zebrafish hepatoblast specification, the source 
of these FGFs has not yet been identified [69, 70]. Fgf10 is expressed in the mesenchymal tissue 
of the extrahepatic structures as well as the liver itself. Since Fgf10-/- mice have smaller livers, 
Fgf10 is dispensable for hepatoblast specification, but important for hepatoblast proliferation [71]. 
This process involves Wnt/-catenin signaling since Fgf10 gain-of-function experiments results 
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in an upregulation of -catenin during liver development, which may be AKT-dependent [72]. 
fgf10a signaling has also been implicated in regulating hepatic competence during zebrafish 
hepatogenesis [73].  
Around E8.25 in mice, FGF signaling (specifically, FGF1 and 2) from the cardiac 
mesoderm [69, 74] were first identified as important for hepatoblast specification in mouse 
explants of foregut endoderm, which also expressed FGF receptors 1 and 4. FGF concentration is 
strictly regulated by the positioning of the STM, which separates the cardiac mesoderm from the 
endoderm [75]. In zebrafish embryos, FGF inhibition resulted in defective hepatoblast 
specification (reduced hhex and prox1a expression) and differentiation (no hepatocyte-specific 
marker expression) [70].  
In addition to FGF, which is necessary but not sufficient for hepatoblast specification, BMP 
signaling from the STM is required for proper endodermal patterning, hepatoblast specification 
and hepatic differentiation [76]. Further information about the role of BMP signaling in liver 
development and liver regeneration is discussed in Section 1.5. 
Wnt signaling also plays an important role in early hepatogenesis. In zebrafish, Wnt2bb 
and Wnt2 are secreted Wnt ligands expressed in the LPM that contribute to hepatoblast 
specification. Wnt signaling mutants, Prometheus (prt), which have defective wnt2bb are 
characterized by small or absent liver buds [28]. However, the defect is transient as these mutants 
eventually recover and can grow into adulthood. This observation indicates multiple Wnts may 
contribute to liver specification: for instance, when wnt2 was additionally knocked down in wnt2bb 
mutants, hhex was not expressed and the liver failed to develop altogether [77]. In mice, however, 
double KOs of Wnt and Wnt2b has no effect on liver development [78, 79]. The study of apc-/- 
zebrafish mutants, which have dysregulated -catenin degradation [80], uncovered the temporal 
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role of Wnt signaling in liver development: induction of Wnt at early somitogenesis blocked liver 
specification, whereas post-somitogenesis Wnt induction is important for hepatoblast 
proliferation, affecting the liver size [40, 81, 82].  
Hepatic competence is retained in the zebrafish endodermal region posterior to the foregut 
endoderm, although this capacity is gradually lost over time. When wnt8a is overexpressed, both 
hepatoblast specification and differentiation are affected: (1) ectopic hepatoblast induction occurs 
in regions previously reserved for intestinal and pancreatic tissues; and (2) hepatoblast 
differentiation markers (sox9b, cp) are induced [73]. At later stages of liver development, Wnt/-
catenin signaling is critical for cell proliferation, survival, hepatocyte maturation and biliary 
differentiation in embryonic liver cultures [83]. 
Following hepatoblast specification, liver bud morphogenesis involves the contribution of 
several factors, including HEX and PROX1. HEX is a homeobox family of transcription factors 
that is expressed in the ventral foregut endoderm and in the liver [84]. Hex KO embryos lack 
several endodermal organs, including liver and ventral pancreas. Although hepatic endoderm 
specification still occurs in Hex KO embryos, the endodermal cells fail to proliferate, causing a 
defect in liver development [85]. Moreover, as Hex is necessary for hepatoblast delamination, Hex-
/- hepatoblasts fail to delaminate and migrate into the STM [85-87]. If Hex is conditionally deleted 
in hepatoblasts, the embryos survive but display an increased BEC proliferation and defective 
morphogenesis of the intrahepatic bile ductules [88]. In zebrafish, hhex morphants showed that 
although hepatoblast specification may have be unaffected, the liver bud failed to form. In fact, 
hhex morphants had additional biliary ductular development defects and did not survive past 2 dpf 
[63]. 
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Prospero homeoprotein (PROX1) is a homeobox-containing transcription factor with a 
helix-turn-helix structure and is important for hepatoblast differentiation and delamination. Prox1-
/- hepatoblasts have elevated levels of E-cadherin, which causes a lack of ECM degradation. As a 
result, these hepatoblasts fail to delaminate and migrate into the STM [89]. Moreover, when Prox1 
is specifically depleted in the hepatoblasts, the mice die at birth due to a defective liver 
morphology. Expression of mature hepatocyte markers (HNF4A, GS, KLF15, APOC2) is 
decreased in Prox1-deficient livers and biliary-related genes are increased (SOX9, KRT19). This 
implicates PROX1 as an important regulator of hepatoblast differentiation in addition to its role in 
hepatoblast migration. Even though biliary differentiation-related genes are upregulated, biliary 
formation is still defective with prematurely formed, large intrahepatic bile ducts. Once 
hepatoblast differentiation has occurred, however, no gene expression differences are observed 
[90].  
Most of the focus thus far has been on signaling important in the early stages of liver 
development. For later stages of hepatogenesis, such as hepatoblast differentiation, one signaling 
pathway that has emerged as a key regulator of BEC differentiation is the Notch signaling pathway. 
Notch is important for BEC development, proliferation, differentiation and biliary morphogenesis 
[67, 91, 92]. Notch signaling promotes a biliary fate, while suppressing a hepatocyte fate [93]. In 
humans, defects in Notch signaling can lead to biliary-associated diseases, such as Alagille 
syndrome, characterized by bile accumulation in the liver. The syndrome is caused by mutations 
in the JAG1 Notch ligand or NOTCH2 receptor proteins [94, 95]. 
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1.4 LIVER REGENERATION 
1.4.1 Overview of Liver Regeneration 
The liver possesses an innate and robust capacity to regenerate. Liver regeneration can manifest in 
one of two ways: (1) hepatocyte-driven or (2) BEC-driven [see Figure 2]. Typically following 
liver injury, hepatocytes proliferate to restore the lost liver mass. This process is termed 
hepatocyte-driven liver regeneration. However, if hepatocyte proliferation is blocked, then the 
BECs undergo dedifferentiation into hepatoblast-like cells (HB-LCs), also termed LPCs. LPCs can 
then differentiate into functional hepatocytes. These two types of liver regeneration will be 
discussed in detail in sections 1.4.3 and 1.4.4, respectively.  
As HB-LCs/LPCs share both hepatocyte and BEC markers, they possess a bipotential 
capacity similar to hepatoblasts. Hence, these progenitor cells have been referred to as 
‘hepatoblast-like cells,’ ‘oval cells,’ ‘ductular cells,’ ‘hepatic progenitor cells’ or ‘liver progenitor 
cells.’ The term ‘oval cell’ was first coined in a rat model of chemical-induced liver carcinogenesis. 
In this liver injury model, the newly-emerging oval cells possessed distinct morphological traits, 
including ovoid nuclei, small size and high nuclei to cytoplasmic ratio [96]. LPCs are also thought 
to reside in a phenomenon termed the ductular reaction (DR). DRs are a heterogeneous cluster of 
duct/cord-like structures that include extracellular matrix components and inflammatory cells [97].  
Throughout the dissertation, these progenitor cells will be referred to as LPCs for ease of 
clarity.  
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Figure 2: A model for the types of liver regeneration 
In mature cell-driven liver regeneration, when hepatocytes or BECs are injured, the remaining cells can 
respectively proliferate and regenerate the lost cells. In contrast, under severe or chronic liver injury, 
when most hepatocytes are damaged and/or become senescent and lose the ability to proliferate, LPC-
driven liver regeneration occurs. In this regeneration process, the remaining BECs can dedifferentiate 
into liver progenitor cells (LPCs), which proliferate and differentiate into mature hepatocytes and/or 
BECs. 
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1.4.2 Hepatocyte Turnover in Physiological Conditions 
No true resident stem cell has been identified in the liver. This is hardly surprising considering that 
under physiological homeostatic conditions and most pathological conditions, hepatocytes can 
quickly execute a regenerative response to replace the functional tissue. Moreover, hepatocyte 
turnover rate is relatively low in adult livers, with a half-life in the range of 8-12 months [98, 99]. 
One explanation for hepatocyte turnover in physiological conditions is the streaming liver 
hypothesis. According to this hypothesis, new hepatocytes originate from the periportal zone 
proximal to the bile ducts. These new hepatocytes then migrate towards the central vein, 
populating the liver parenchyma [100]. Evidence for this hypothesis remains controversial. In one 
lineage tracing study with X-gal staining, the tamoxifen-inducible CreERT2 construct was inserted 
into the Sox9 (a BEC marker) locus [101]. Initially, X-gal positive hepatocytes were observed 
spreading from the periportal bile ducts towards the central vein region; over time, X-gal positive 
hepatocytes could be detected throughout the entire liver parenchyma. However, separate studies 
which used different strains to label BECs, such as the SOX9-CreERT2 BAC transgenic or the 
osteopontin (OPN)-CreERT2, found no evidence to prove the streaming liver model of hepatocyte 
turnover [36, 102]. Hence, further study is needed to unequivocally name the liver cell responsible 
for hepatocyte turnover in homeostatic, physiological conditions.  
1.4.3 Hepatocyte-driven Liver Regeneration 
In pathological conditions and most liver injury models, such as partial hepatectomy (PHx), there 
is no involvement of resident ‘stem cells.’ Instead, mature hepatocytes proliferate to restore the 
liver parenchyma. First described in 1931 by Higgins and Anderson, PHx is an example of a 
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compensatory mechanism of regeneration [103]. After a 70% excision – or a 2/3 resection – of the 
liver lobes, the remaining hepatocytes proliferate to compensate for the lost liver mass. The liver 
fully recovers by 5-7 days post-PHx. Initial research studies using radiolabeled thymidine 
incorporation in hepatocytes showed that nearly all hepatocytes proliferate post-PHx [104, 105]. 
However, mouse studies of PHx with lineage tracing has shown that although most hepatocytes 
enter the S phase of the cell cycle, not all hepatocytes proceed to the M phase and divide. In fact, 
liver regeneration post-PHx initially manifests as a hypertrophic event and later as a proliferation 
event [106].  
The regenerative response post-PHx involves a priming and a replicative phase. The 
priming phase is marked by cytokine production and release of growth factors that activate 
downstream transcription factors, such as signal transducer and activator of transcription 3 
(STAT3). The replicative phase involves two rounds of DNA replication events with the peak 
hepatocyte replication occurring at 24h post-PHx in rats and 36h in mice. Hepatocytes are the first 
liver cells to enter DNA synthesis followed by BECs, HSCs and then endothelial cells. Several 
factors have been identified to be important mediators of the regenerative response post-PHx. 
These include hepatocyte growth factor (HGF)/tyrosine-protein kinase Met (c-Met) [107, 108], 
epidermal growth factor (EGF)/EGFR, interleukin-6 (IL6)/STAT3 [109, 110], tumor necrosis 
factor (TNF)/tumor necrosis factor receptor 1 (TNFR1) [111] and transforming growth factor beta 
(TGFB) [112]. Following PHx, known hepatocyte mitogens, HGF and EGF, are activated [113]. 
If their cognate receptors, c-Met or EGFR, are both inhibited prior to PHx, then proper regeneration 
fails to occur [114]. In addition, PHx also results in an upregulation of non-mitogenic factors, such 
as IL-6, norepinephrine, insulin and TNF. These factors enhance signals regulating hepatocyte 
proliferation.  
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In addition to mice and rats, PHx has also been modeled in adult zebrafish. In zebrafish, 
following a 1/3 resection of the liver lobes, the liver recovers to its original size 7 days post-PHx 
[27]. Hepatocyte regeneration manifests as the re-entry of the remaining hepatocytes into the cell 
cycle. In zebrafish, the cell cycle regulator, Uhrf1, was found to be an important regulator of 
hepatic outgrowth and liver regeneration; in fact, after PHx, uhrf1+/- mutants failed to recover their 
liver size. Although zebrafish exhibit epimorphic regeneration upon injury in several organs (i.e., 
heart, eye), Interestingly, it remains unclear whether following PHx, zebrafish liver regeneration 
is a compensatory (as occurs in higher vertebrates and involves proliferation of remnant lobes) or 
an epimorphic (true regeneration in which hepatocytes proliferate from the missing lobe) event 
[27, 115].  
Clinically, although PHx does not represent any pathological condition of human liver 
disease, this model of liver injury still provides relevant information about mechanisms involved 
in hepatocyte-driven liver regeneration for living donors providing partial liver transplants. 
1.4.4 BEC- or LPC-driven Liver Regeneration 
Although mature liver cells possess the incredible ability to regenerate, this ability is in jeopardy 
once hepatocyte proliferation is compromised, as occurs in cases of chronic viral hepatitis or 
alcoholic liver disease. In such scenarios, oval cells or LPCs emerge as the progenitor cells 
accountable for mediating liver regeneration. Thought to arise from the periportal regions (or 
canals of Hering), LPCs are bi-potent, facultative resident progenitor cells with the ability to 
differentiate into hepatocytes and BECs [116, 117]. LPCs express hepatocyte (M2-PKm, 
Albumin), BEC (EpCAM, CK-19, Osteopontin, Sox9) [116, 118] and markers specific to their 
progenitor cell status (LGR5, FOXL1, TROP2) [119, 120]. TROP2 expression only appears in 
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LPCs after DDC-induced liver injury and is absent in BECs of uninjured livers. Using transgenic, 
knockin mouse lines, leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) was also 
shown to be expressed specifically in LPCs post-liver injury. Additional co-markers used to 
identify LPCs include CD133 and MIC1-1C3 [121-124].  
Due to the bi-potential progenitor cell nature of LPCs, it is reasonable to consider the canal 
of Hering, a junctional region located strategically between the hepatocyte parenchyma and the 
biliary compartment, as a niche from which post-injury-specific LPCs arise. However, this notion 
remains to be proven. LPCs are thought to arise from pre-existing BECs since LPCs and BECs are 
phenotypically alike [125]. However, hepatocytes can also act as facultative progenitor cells in 
cases of BEC injury, such as bile duct ligation (BDL), to restore the BEC number and function 
[126, 127].   
Several animal models of LPC activation have been established, including the rat 2-
acetylaminofluorene (2-AAF)/PHx model of liver injury [128], the mouse 3,5-diethyoxycarbonyl-
1,4-dihidro-collidine (DDC)-containing diet, the choline-deficient ethionine-supplemented diet 
(CDE) of liver injury [129, 130], the hepatocyte-specific deletion of Mdm2 (a p53 inhibitor) model 
of liver injury [131] and the zebrafish hepatocyte-specific genetic ablation model [20, 132]. In the 
2-AAF/PHx rat model, 2-AAF is administered before PHx to block hepatocyte proliferation, as 
measured by the absence of PCNA-positive nuclei, p53 induction and increased p21 levels [133]. 
Although the 2-AAF/PHx rat model effectively activates an oval cell response, it is limited by the 
difficulty of pursuing lineage tracing experiments in rats. Alternative options include the mouse 
DDC and CDE diet models of liver injury. In the DDC diet, heme biosynthesis is blocked, inducing 
hepatocyte damage and subsequent periportal cell proliferation. On the other hand, the CDE diet 
causes fatty liver disease in mice and models alcoholic liver disease or nonalcoholic 
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steatohepatitis. Initial injury manifests as steatosis and LPC activation/proliferation, while long-
term exposure results in a fibrotic and cirrhotic phenotype, eventually leading to hepatocellular 
carcinoma (HCC) [134]. Although the aforementioned models activate LPCs, the main concern is 
that the induced LPCs are not all the same, with rat oval cells displaying distinct markers (Dlk/Pref-
1, AFP) not observed in the mouse liver injury models [135]. In the mouse Mdm2 KO genetic-
inducible model, AhCre system with an Mdm2 floxed genetic system was used to express Cre 
recombinase upon B-napthoflavone treatment. Upon Cre activation, Mdm2, which promotes p53 
degradation, was blocked in the majority (>98%) of hepatocytes. Thus, p53 was upregulated and 
resulted in hepatocyte apoptosis, necrosis and even senescence. As a result, there was a robust 
response of LPC activation, proliferation and subsequent differentiation into mature hepatocytes. 
Finally, the zebrafish hepatocyte-specific genetic ablation model involves complete hepatocyte 
ablation and subsequent LPC activation, proliferation and differentiation into hepatocytes and 
BECs. This zebrafish model will be discussed further in section 1.4.5.  
Using these models, several studies have sought to elucidate key factors and pathways 
relevant for the regulation of LPC-driven liver regeneration. These factors and pathways include 
TWEAK, HGF/c-Met, BET proteins, NOTCH, WNT and FGF pathways. Among these factors, 
the LPC mitogen, TNF-like weak inducer of apoptosis (TWEAK), acts through its receptor, FN14 
[136-138]. In transgenic mice with TWEAK overexpression, oval cell and BEC proliferation (with 
no mitogenic effect on mature hepatocytes) was significantly increased even in the absence of any 
liver injury. Moreover, in a DDC diet model of liver injury, inhibition of TWEAK also prevented 
oval cell proliferation. Whereas in a Mdm2 KO model of liver injury and LPC activation, a 
deficiency in FN14 prevented the proper induction of a ductular reaction, addition of TWEAK 
enhanced the ductular reaction response [131].  
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Another factor, FGF7, is also important for regulating LPC expansion. In serum samples 
obtained from human patients of fulminant hepatic failure/acute hepatitis, FGF7 levels were 
increased. In mouse DDC and BDL models of liver injury, expression of Fgf7 was highly 
upregulated near the LPCs [139]. Similar to TWEAK, forced overexpression of Fgf7 in non-
injured livers caused significant increase in the number of CK19-positive LPCs near the periportal 
regions. Fgf7 KO mice on a DDC diet or BDL injury exhibited low survival, a block of LPC 
activation and a decrease in proliferation of CK19-positive LPCs.  
Besides its known role in hepatocyte-driven liver regeneration, the growth factor signaling 
pathway involving HGF/c-Met is also important for LPC-driven liver regeneration [140]. In a 
DDC model of liver injury, upon deletion of Met in LPCs using the Alb-Cre (epithelial cells) and 
Mx1-Cre (stromal) lines, LPC proliferation, migration and differentiation into hepatocytes was 
significantly impaired. MET or EGFR deletion and overexpression in vitro established the 
contrasting roles these receptors play in cell fate decisions [141]. While MET – via STAT3/AKT 
– is an important regulator of LPC-to-hepatocyte differentiation, EGFR – through its mediation of 
NOTCH1 – is important for LPC-to-biliary cell fate commitment and ductular morphogenesis.  
NOTCH and WNT signaling can also regulate LPC-mediated liver regeneration [142]. In 
a DDC model of liver injury, LPCs require NOTCH signaling for proper biliary cell fate 
commitment and WNT for proper hepatocyte cell fate commitment during regeneration. Following 
biliary injury, a Notch-associated ligand, JAGGED1, is released from myofibroblasts and interacts 
with the Notch receptor present on proximal LPCs. For hepatocyte recovery, hepatic Kupffer cells 
release WNT3A proximal to activated LPCs, which produce Numb to block Notch signaling and 
instead activate a hepatocyte differentiation pathway.  
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In addition to murine models, the zebrafish model has been used successfully to elucidate 
underlying mechanisms of LPC-driven liver regeneration. Blocking bromodomain and 
extraterminal (BET) proteins negatively affects several key steps of LPC-driven liver regeneration, 
including BEC dedifferentiation into LPCs, LPC proliferation and subsequent LPC differentiation 
into mature hepatocytes [143].  
Furthermore, Stueck et al. recently reported on evidence for LPC/BEC-driven liver 
regeneration in human liver samples of chronic liver disease patients. The progression of ‘bud’ 
development was recorded. Bud development was defined as clusters of hepatocytes and bile 
ductules derived from BEC-sourced LPCs. Newly generated hepatocytes (70% from buds) were 
found near the terminal ducts from which they emerged to populate the liver parenchyma. 
Immature hepatocytes expressed both EpCAM and GS (glutamine synthetase), BEC-specific and 
hepatocyte-specific markers, respectively. However, this dual expression later disappeared as 
hepatocytes matured [144]. The authors concluded that in cirrhotic livers the LPCs, which are most 
likely derived from the BECs, contribute to hepatocyte repopulation of the liver parenchyma.  
Insights about LPC-mediated liver regeneration derived from these important studies will 
help in the creation of novel therapeutics to enhance innate liver regeneration and combat liver 
disease in patients. 
1.4.5 Zebrafish LPC-driven Regeneration Model 
Using lineage tracing methods, a recently established model of LPC activation in larval and adult 
zebrafish is characterized by BEC contribution to LPC activation after total hepatocyte loss [20, 
132] [see Figure 3]. In this model the transgenic line, Tg(fabp10a:CFP-NTR), is used to express 
Escherichia coli bacterial nitroreductase (NTR) enzyme fused with the cyan fluorescent protein 
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(CFP) from the hepatocyte-specific fabp10a promoter. When fish are treated with metronidazole 
(Mtz), a prodrug, cells expressing NTR metabolize Mtz into a cytotoxic metabolite. At first, 
NADH or NADPH can both reduce NTR [145]. Upon Mtz addition, NTR reduces Mtz and 
converts it into a cytotoxic agent – essentially a powerful DNA interstrand cross-linking compound 
– that induces cell death in NTR-expressing cells [146-148]. In Tg(fabp10a:CFP-NTR) zebrafish, 
CFP can be detected as early as 2.5 dpf and Mtz is treated at 3.5 dpf for a 36-hour treatment [149]. 
After Mtz treatment, all hepatocytes expressing CFP-NTR will undergo cell death (i.e., apoptosis), 
corresponding to severe liver damage. Following Mtz washout at 5 dpf, since hepatocytes can no 
longer contribute to the regenerative response, BECs now assume control of liver regeneration in 
a three-step process: (1) All BECs dedifferentiate into LPCs, which co-express Hnf4a (a 
hepatoblast/hepatocyte marker) and Prox1 (a hepatoblast/hepatocyte/BEC marker) in Alcam-
positive (a BEC marker) BECs; (2) LPCs proliferate; and (3) LPCs differentiate into hepatocytes 
and BECs to reconstitute the lost liver mass. Using this zebrafish liver injury model, we sought to 
elucidate the underlying mechanisms of LPC-driven liver regeneration, specifically focusing on 
BMP and Stat3 signaling pathways.  
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Figure 3: LPC-driven liver regeneration model in zebrafish 
(A) Schematic for the cassette expressing the cerulean fluorescent protein (CFP) fused to the 
nitroreductase (NTR) gene from a tissue-specific (tsp) promoter. Specific cells (blue) express this 
transgene prior to ablation. After metronidazole (Mtz) treatment, cells expressing this transgene (blue) 
are specifically and genetically ablated (black). Bystander or surrounding NTR-negative cells are 
unharmed. (B) Epifluorescence images of a 5-dpf zebrafish larvae expressing CFP (blue) fused to NTR 
from the hepatocyte-specific promoter, fabp10a, and nuclear mCherry (red) in Notch-signaling cells. 
The white dashed lines outline the liver region. (C) Confocal time-course images of control (non-
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ablated) and regenerating livers following a 36-hour Mtz treatment. After Mtz washout, liver 
regeneration (R) begins. In addition to Tg(fabp10a:CFP-NTR) and Tg(Tp1:H2B-mCherry) lines, the 
Tg(Tp1:Venus-PEST) highlights active Notch signaling in the BECs. The liver fully regenerates by 
R102h post-Mtz washout. (D) Overview of the hepatocyte damage (ablation: A) and steps of liver 
recovery (regeneration: R). Larvae are treated with Mtz at 3.5 dpf for 36 hours. Upon Mtz washout at 5 
dpf, liver regeneration can be monitored. At A18h, due to intense hepatocyte cell ablation, 
macrophages infiltrate into the liver. At A36h/R0h, all BECs have dedifferentiated into HB-LCs/LPCs 
to begin the regeneration process. Following dedifferentiation, the liver undergoes intensive periods of 
proliferation and differentiation of LPCs into either hepatocytes or BECs. Scale bars: 250 µm (B); 20 
µm (C). 
1.5 BMP SIGNALING PATHWAY 
1.5.1 Overview of the BMP Signaling Pathway 
Originally discovered in 1965 and now classified as regulators of bone formation, Bone 
Morphogenetic Proteins (BMPs) are extracellular cytokines and members of the superfamily of 
Transforming Growth Factor-B (TGF-B) [150]. The evolutionarily conserved canonical TGF-
B/BMP signaling pathway is involved in a diverse array of vertebrate physiology, including 
homeostasis, embryo patterning, cell fate determination, injury response and organ development 
[151-154].   
In the canonical BMP pathway, BMP ligands are synthesized in an inactive precursor form. 
Following a proteolytic cleavage event, inactive BMP ligands dimerize and become active. Active 
BMPs bind to the serine/threonine BMP type I and type II receptors (BMPRs). The kinase domain 
of type II BMPR phosphorylates type I BMPR; the latter then activates the SMAD signaling 
 28 
pathway by phosphorylating SMAD1/5/8. A heteromeric complex forms when SMAD1/5/8 
associate with the common SMAD, SMAD4, which translocates to the nucleus and activates 
expression of downstream target genes, such as id2a and tbx2b [155, 156] [see Figure 4]. 
Alternative, non-canonical BMP, SMAD-independent pathways also exist, signaling through 
MAPK cascade, the PI3K/AKT and/or Rho-GTPases [157-159]. Both the non-canonical and 
canonical pathways can be regulated by the BMP ligands extracellularly or intracellularly via 
phosphatases, inhibitory SMADs, miRNAs, Chordin/Noggin proteins, as well as crosstalk with 
other signaling pathways [160]. 
 
Figure 4: Schematic of the canonical BMP signaling pathway 
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In canonical BMP signaling, BMP ligands dimerize and bind to the serine/threonine BMP type I and 
type II receptors, activating them. Type I BMP receptor phosphorylates Smad 1/5/8. Upon activation, 
Smad 1/5/8 associates with Smad4 and the entire heterotrimeric complex translocates to the nucleus 
and activates expression of downstream target genes (i.e., id2a and tbx2b). DMH1, a small molecule 
inhibitor, blocks BMP signaling by specifically targeting BMP Type I receptors.  
1.5.2 BMP Signaling in Liver Development 
Due to their pleiotropic effect, BMPs are essential for the proper development and function of 
various organs (reviewed in [160]) [161, 162], as evidenced by the non-viability of Bmp2 or Bmp4 
knockout mice. For example, complete absence of Bmp2 or 4 is embryonic lethal due to defects in 
heart and mesoderm development, respectively [163, 164]. In mammalian liver development, BMP 
signaling from the STM is essential, but not sufficient, for induction of hepatic cell fate [76, 165] 
over pancreas specification [166]. Moreover, BMP signaling may affect Gata4 levels, thereby 
regulating hepatic competence during liver development [70]. Specifically, BMP4 is one of the 
few secreted proteins that are involved in standard morphogenesis and growth of the hepatic 
endoderm as well as formation of the liver bud [76]. Inhibition of the BMP pathway blocks hepatic 
induction in mice [76, 165].  
In zebrafish, a common endodermal progenitor cell was identified that can give rise to both 
the ventral pancreas and the liver. The location of cells from the bmp2b-secreting LPM determines 
the cell fate: cells located medially adopted a pancreatic/intestinal fate, whereas cells located 
laterally adopted a hepatic fate. Bmp2b regulates cell fate by blocking pdx1 expression in cells 
adjacent to the medial cells, which will give rise to the liver [167]. In addition, Bmp2a is required 
for liver formation. In zebrafish studies, when BMP signaling was blocked early using either a 
dominant-negative BMPR or alk8 mutants, hepatoblast specification was inhibited, most likely 
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due to decreased expression of Gata4. If, however, BMP signaling is blocked at the post-hepatic 
specification stage, there is little effect on the maintenance of the liver progenitors [70]. 
1.5.3 BMP Signaling in Liver Regeneration 
Although TGF-B and activin A have been characterized as negative regulators of liver 
regeneration, BMPs are thought to promote liver regeneration. For example, in a mouse model of 
partial hepatectomy, regeneration was regulated, in part, by the BMP signaling pathway. Not only 
was the expression of the type II BMP receptor, Alk3, upregulated, but treatment with recombinant 
human BMP7 led to enhanced hepatocyte proliferation and liver regeneration. Moreover, blocking 
endogenous BMP7 resulted in a delayed liver regenerative response [168].   
In contrast to the requirement of BMP7 for liver regeneration after partial hepatectomy, 
BMP4 must be downregulated. In fact, if BMP4 expression is artificially enhanced after partial 
hepatectomy, then hepatocyte proliferation is significantly decreased and liver regeneration 
impaired. On the other hand, if BMP4 was blocked, hepatocyte proliferation was increased, 
indicative of enhanced liver regeneration [169]. One way to consolidate the two differing 
observations of BMPs is the thought that BMP7 and BMP4 act through different receptors, with 
the latter inhibiting and the former enhancing, respectively, liver regeneration. For example, when 
ALK3 is blocked prior to partial hepatectomy, hepatocyte proliferation is increased; however, 
when ALK2 is blocked there is no effect, or even a slight decrease, in hepatocyte proliferation 
[170].   
Similarly, when BMP signaling is blocked in the adult zebrafish partial hepatectomy 
model, the liver mass is transiently reduced at day 7 days post-partial hepatectomy, but is back to 
normal size by 9 days post-partial hepatectomy. Moreover, in vitro treatment of BMP2 enhances 
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hepatocyte proliferation and upon co-treatment of BMP2 and the BMP antagonist, Noggin, the 
enhanced proliferation effect is gone [115].   
One known downstream target gene of the BMP pathway is the Inhibitor of DNA binding 
2 (ID2) protein. In zebrafish, since Id2a is expressed in the hepatoblasts and BECs of the liver, 
Chapter 2 of this dissertation will focus on the effect of id2a deficiency on liver development. 
Although the role of BMP signaling in liver development has been established, its role in LPC-
driven liver regeneration has not yet been elucidated. In our zebrafish LPC-driven liver 
regeneration model, we found several components of the BMP pathway as well as id2a to be 
upregulated at multiple stages of the regeneration process. Thus, Chapter 3 of this dissertation will 
focus on the effect of BMP signaling and its downstream target gene, id2a, on LPC-driven liver 
regeneration.   
1.5.4 Helix-loop-helix Factors and Inhibitor of DNA Binding Proteins BMP Signaling in 
Liver Regeneration 
Conserved from yeast to humans, helix-loop-helix (HLH) group of proteins consists of more than 
240 members categorized into 7 groups, including Class I (E proteins with E-box sites), Class II 
(heterodimerize with E-proteins), Class III (leucine zipper-containing in addition to the HLH 
motif), Class IV (dimerize with Myc, Mad, Max or Mxi), Class V (Id proteins), Class VI (proline-
containing) and Class VII (contain a bHLH-PAS domain). Common among all classes of HLH is 
the helix-loop-helix domain – also termed the dimerization domain [171]. Most HLH proteins 
possess a basic domain, which allows for DNA binding to specific DNA target sequences, such as 
E-boxes (CANNTG) or N-boxes (CACNAG). Some HLH proteins contain a PAS domain, which 
is a signaling sensor of environmental conditions and stress and provides additional dimerization 
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motifs, while some HLH factors possess a domain at the C-terminus that is involved in co-repressor 
interactions. Still others, like the Id proteins, lack the DNA-binding domain and instead act as 
negative regulators [172, 173]. HLH proteins form either homo- or heterodimers and function in 
regulating cell cycle control, cell fate commitment and differentiation; moreover, HLH proteins 
are involved in important developmental processes, such as pancreatogenesis, myogenesis and 
neurogenesis [174-176].   
Typically, organogenesis requires regulatory signals, extracellular or intracellular, to 
properly control cell proliferation and differentiation. Id proteins belong to the HLH family that 
lacks the basic DNA binding domain. Besides their known function to positively regulate 
proliferation and negatively regulate differentiation in vertebrates and invertebrates [177-180], Id 
proteins are also involved in the regulation of senescence, cell fate commitment, apoptosis and 
tumorigenesis [181-184]. In mammals, four Id proteins have been discovered, including ID1, ID2, 
ID3 and ID4 [172, 180, 185, 186]. Mechanistically, Id proteins act in a dominant negative fashion 
by dimerizing with other bHLH transcription factors through their HLH domain, essentially 
sequestering the bHLH factors, preventing their dimerization with their partner and subsequently 
regulating transcription [177].  
The structure of Id proteins consists of the HLH domain and variable N and C-terminal 
regions. The N-terminal region of Id2 protein can be ubiquitinated and primed for degradation 
[187] and is also involved in inducing apoptosis [188], whereas the C-terminus contains a nuclear-
cytoplasmic transport [189]. Id2 can bind both bHLH (E proteins) as well as non-bHLH proteins, 
such as the Retinoblastoma protein (Rb); in the latter case, Id2 antagonizes Rb protein’s ability to 
act as a growth suppressor. Because of its role in regulating the cell cycle, Id expression has been 
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shown to be upregulated in various types of cancers, including neuroblastoma [190], pancreatic 
cancer [191] and prostate cancer [192].  
The zebrafish genome contains five Id proteins, including Id1, Id2a, Id2b, Id3 and Id4. 
Previously, two developmental studies in zebrafish have implicated id2a in the role 
of retinogenesis regulating the cell cycle. In particular, Id2a was essential in the transition from 
the S to M phase of the cell cycle and subsequent retinal cell differentiation [193].  During the G1-
S transition, it is thought that ID proteins are released from phosphorylated Rb protein to 
negatively regulate other bHLH factors [182]. In our zebrafish model of LPC-driven liver 
regeneration model, id2a was upregulated throughout the regeneration process. Since many 
pathways active during development may also be recapitulated during regeneration, we sought to 
investigate the role of Id2a in liver development as well as regeneration. 
1.6 INFLAMMATORY SIGNALING IN LPC-DRIVEN LIVER REGENERATION 
1.6.1 Overview of the Stat3 Signaling Pathway 
Signal transduction and activator of transcription (STAT) protein 3, also termed the acute phase 
response factor (APRF), is an important transcription factor and mediator of development, 
homeostasis, disease pathology and response. The STAT family of proteins consists of 7 members 
in mammals (STAT1, 2, 3, 4, 5a, 5b and 6) and, due to a genome duplication event, 8 members in 
zebrafish (Stat1a, 1b, 2, 3, 4, 5a, 5b and 6). Zebrafish Stat3 contains 3 splice variants and is 86.5% 
homologous to the mouse STAT3 protein [194]. Stat3 is composed of 6 distinct domains, including 
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coiled-coil, Src homology domain (SH2), DNA-binding, N-terminal and the transactivation 
domains. 
STAT3 signaling initiates when cytokines or growth factors bind to their cognate receptors, 
resulting in downstream autophosphorylation and subsequent activation of the Janus kinases 
(JAKs) [195]. Activated JAKs then phosphorylate STATs at the Tyr705 site, which homo- or 
heterodimerize to other STATs through binding to the SH2 domain, and translocate to the nucleus 
to regulate transcription of numerous target genes [see Figure 5]. Besides being activated by JAKs, 
STAT3 proteins can also be phosphorylated (i.e., activated) at the Ser727 site by ERK, ATR and 
CDK1 [196]. Interestingly, unphosphorylated STAT3 can also translocate to the nucleus and 
influence transcription of downstream genes [197]. Traditionally, the downstream genes have been 
reported to be important for survival, proliferation and differentiation [198]. In the liver, IL-6 
family of cytokines, IL-22 from Th17 cells, and IFN-A/B from virus-infected cells [199] can all 
activate STAT3 in hepatocytes, which aids in survival, proliferation and regeneration.   
Multiple cytokines can activate STAT3 in Kupffer cells, including the IL-6 family of 
cytokines (IL-6, LIF-1, IL-11) [11]. Liver Kupffer cells express both IL-6 and IL-10 receptors (IL-
6R, IL-10R). As both IL-6 and IL-10 can activate STAT3, but can have varying effects 
downstream (pro-inflammatory vs. anti-inflammatory, respectively), the question arises how such 
an activation is mediated. One study suggests that when IL-6 cytokines, released from multiple 
cell types, bind to IL-6R, STAT3 is transiently activated, causing a pro-inflammatory response. In 
contrast, when IL-10 binds to IL-10R, STAT3 activation is lengthened, resulting in an anti-
inflammatory response. Moreover, this response appears to be modulated by SOCS3 [200, 201].   
One of the key negative regulators and downstream targets of STAT3 is the family of 
suppressor of cytokine signaling (SOCS) genes. In a negative feedback manner, SOCS proteins 
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aim to inhibit cytokine signaling by one of two methods: (1) Through their SH2 domains or kinase 
inhibitory region (KIR) [202], SOCS proteins can directly bind to active JAKs or phosphorylated 
tyrosine 757 (Tyr757) on gp130/cytokine receptors and inhibit their kinase activity or (2) Through 
their SOCS box, SOCS proteins can also target their binding partner for proteosomal degradation 
[203]. However, independent of cytokine signaling, SOCS proteins can also be activated by 
alternative stimuli, including cyclic AMP (cAMP), LPS and statins and can also regulate other 
pathways, such as TLR signaling independent of STAT3 [204, 205]. While mammalian SOCS 
proteins consist of eight members (SOCS1-7, CIS), the zebrafish SOCS protein family is 
composed of 12 members (Socs1a, 1b, 2, 3a, 3b, 4, 5a, 5b, 6a, 6b, 7 and 9). Each SOCS protein 
contains a central SH2 domain, variable N-terminal domain and a conserved C-terminal SOCS 
box. The SOCS box is important for the recruitment of ubiquitin transferases, which may allow 
SOCS proteins to function as E3 ubiquitin ligases [206]. 
 
 36 
 
Figure 5: Schematic of the Stat3 signaling pathway  
Upon binding of cytokines (i.e., interleukin-6) to their cognate cytokine receptors (i.e., interleukin-6 
receptor), the receptors dimerize and undergo a conformational change. Downstream, the Janus kinases 
(Jaks) are phosphorylated and subsequently phosphorylate Stat3 proteins at the Tyr705 site, resulting 
in their activation. Stat3 proteins dimerize and translocate to the nucleus where they bind to gene 
promoters to regulate downstream transcription of many cellular processes, including cell proliferation, 
survival and migration. Two Stat3 inhibitors include JSI-124 (cucurbitacin I) and S3I-201. While JSI-
124 specifically targets the Jaks upstream of the Stat3 pathway, S3I-201 prevents the dimerization of 
Stat3 proteins.   
1.6.2 Role of Stat3 and Socs3 in Liver Regeneration 
During the liver regeneration process at 12-18h post-PHx, the initiation step involves the 
recruitment and release of numerous immune cells, cytokines and components of the innate 
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immune system. Shortly after PHx, IL-6 is upregulated and this activation results in STAT3 
activation downstream. Moreover, Socs3 expression is also enhanced during this time, indicating 
the Stat3 and Socs3 activation are IL-6 dependent [207].  
Socs3 KO mice are embryonic lethal, whereas hepatocyte-specific (using Albumin-Cre) 
Socs3 KO mice display enhanced liver regeneration. After PHx, Socs3 KO mice exhibited an 
increase in hepatocyte proliferation, cell cycle progression and develop hepatocellular carcinoma 
(HCC). In addition, when hepatocytes were isolated from the Socs3 KO mice in culture, they 
proliferated at an increased rate compared to the wild-type [208].  
In most animal models of liver injury tested, interruption of the components in the 
inflammatory signaling pathway, such as oncostatin M (OSM), IL-6/gp130, IL-11 or STAT3, can 
further exacerbate the injury. For instance, IL-11, a member of the IL-6 family of cytokines, was 
found to be upregulated by hepatocytes following acetaminophen-induced acute liver injury as a 
result of dying hepatocytes releasing reactive oxygen species (ROS). This caused the released IL-
11 to bind to IL-11R on neighboring healthy hepatocytes, activating STAT3 downstream and 
resulting in a compensatory proliferation for liver recovery [209]. Moreover, when the pro-
inflammatory cytokine, IL-22, is overexpressed in the mouse liver, hepatocellular damage induced 
by T-cell-mediated hepatitis is non-existent [210].  
In hepatocyte-specific Stat3 KO mice, depending on the type of liver injury, different 
responses were observed: (1) in a CCl4 model of liver injury, liver inflammation was increased; 
(2) in a LPS-induced liver injury, liver inflammation was decreased. However, the role IL-6 plays 
in liver regeneration has had several conflicting reports. During PHx-induced liver regeneration, 
one study reported that IL-6 KO mice displayed an absence of Stat3 activation, increased mortality, 
decreased hepatocyte proliferation and downregulation of multiple cell cycle genes, including 
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Myc, Cyclin D and AP1 [211]. A separate group reported that following PHx in IL-6 KO mice, 
hepatocyte proliferation was only decreased by 20-30% with no change in mortality rate between 
sham controls and injured mice [212]. A third group reported that following PHx in IL-6 KO mice, 
no difference in hepatocyte proliferation was observed; however, IL-6 KO mice had increased 
mortality compared to wild-type mice [109].  
Following acute liver injury, such as PHx, Socs3 expression was upregulated almost 40 
times compared to sham controls. Interestingly, deletion of Socs3 in the liver resulted in 
hyperactivation of STAT3 in the liver as it caused an increase in IL-6-mediated phosphorylation 
of STAT3. Moreover, Socs3 deletion in the liver enhanced hepatic fibrosis through production of 
TGF-B1 [213].  
In a CDE-diet mouse model of liver injury and oval cell activation, IL-6 levels were also 
upregulated and IL-6 KO mice displayed a reduction in total oval cell numbers. In fact, similar to 
the PHx liver injury case, Socs3 levels were also enhanced in mice given a CDE diet. When CDE-
diet mice were stimulated with IL-6, Socs3 expression was increased in liver progenitor cells in 
vivo. In vitro, when oval cells in culture were stimulated with IL-6, Socs3 expression was also 
increased [214].  
1.7 MAJOR HYPOTHESIS 
Using the zebrafish LPC-driven liver regeneration model, we were interested in studying the 
process of LPC differentiation into hepatocytes and BECs. To elucidate mechanisms underlying 
LPC differentiation, we used RNAseq to narrow our focus onto two main pathways, including (1) 
the BMP signaling pathway and its downstream target gene, id2a, and (2) the Stat3 immune 
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signaling pathway. No previous literature discusses the role of Id2a in liver development and the 
role of Id2a or Stat3 following complete hepatocyte ablation injury and subsequent LPC-driven 
liver regeneration.  
For this dissertation, we had two main hypotheses. First, we hypothesized that Id2a was an 
important regulator of hepatoblast/hepatocyte proliferation and biliary morphogenesis in liver 
development and an important mediator of LPC-driven liver regeneration, acting downstream of 
the BMP signaling pathway. Second, we hypothesized that Stat3 and Socs3a were important 
mediators of LPC-to-hepatocyte and -BEC differentiation during LPC-driven liver regeneration.  
1.7.1 AIM 1: Elucidate the Role of Id2a in Zebrafish Liver Development  
Preliminary studies suggest that id2a is expressed in the developing zebrafish liver beginning 30 
hpf and is maintained in the structure of the biliary network following hepatoblast differentiation. 
Moreover, it is known that Id proteins act downstream of the BMP signaling pathway in various 
developmental processes [F31 55]. Hence, we hypothesized that Id2a is not only required for 
hepatoblast/hepatocyte proliferation and in the formation of a proper biliary network, but it is also 
the downstream target of BMP signaling during liver development. To evaluate this hypothesis, 
we sought to examine the outcome on hepatoblast/hepatocyte proliferation, survival and biliary 
morphogenesis following id2a knockdown and in id2a mutants. The findings from these studies 
are highlighted in Chapter 2.   
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1.7.2 AIM 2: Determine the Impact of the BMP Signaling Pathway and Downstream 
Target Gene, id2a, in Zebrafish LPC-driven Liver Regeneration 
Following hepatocyte-specific genetic ablation in zebrafish and during LPC-driven liver 
regeneration, RNAseq analyses and RT-PCR data indicate an upregulated expression of id2a and 
BMP pathway components in the regenerating livers. This upregulation is maintained during the 
dedifferentiation of BECs, appearance of HB-LCs/LPCs and the redifferentiation step of HB-
LCs/LPCs into hepatocytes. Furthermore, preliminary data from our lab suggest that inhibition of 
the BMP signaling pathway compromises LPC-driven liver regeneration. Hence, we hypothesized 
that Id2a is an important downstream target of BMP signaling during LPC-driven liver 
regeneration and that Id2a is also an important regulator of this process. To evaluate this 
hypothesis, we sought to: (1) determine whether the process of BECs dedifferentiation, HB-
LCs/LPCs proliferation and/or hepatocyte redifferentiation is compromised in id2a mutants; and 
(2) chemically and genetically inhibit BMP signaling using DMH1 and smad5 mutants, 
respectively, to examine effect on LPC-driven liver regeneration, including proliferation, survival, 
differentiation and functional recovery of hepatocytes and BECs. The findings from these studies 
are highlighted in Chapter 3.  
1.7.3 AIM 3: Elucidate the Role of Stat3 in LPC-driven Liver Regeneration 
The final aim of this dissertation was formulated with the interest of studying the initial stages of 
BEC dedifferentiation after liver injury. RNAseq data generated in our lab showed that both stat3 
and socs3a were upregulated during LPC-driven liver regeneration. To address the importance of 
Stat3/Socs3a signaling in LPC-driven liver regeneration, we blocked Stat3 using a chemical 
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inhibitor, JSI-124, and examined the effect on LPC-driven liver regeneration. Preliminary data 
indicated that treatment with Stat3 inhibitor decreased the size of regenerating livers. Thus, we 
hypothesized that Stat3 and its negative feedback regulator, Socs3a, were necessary mediators for 
proper LPC-driven liver regeneration. Specifically, we utilized both JSI-124 inhibitor treatment as 
well as stat3 TALEN mutants to explore the effect of stat3 deficiency on LPC-driven liver 
regeneration. The result of smaller regenerating livers was indicative of either a retention of LPCs 
in their progenitor state or a defect in hepatocyte/BEC differentiation, proliferation and/or 
apoptosis. The data highlighting the findings from this hypothesis are presented in Chapter 4 and 
Appendix B.  
 42 
2.0  ID2A IS REQUIRED FOR HEPATIC OUTGROWTH DURING LIVER 
DEVELOPMENT IN ZEBRAFISH 
2.1 BACKGROUND 
Liver organogenesis is a multifaceted process involving hepatoblast specification from the ventral 
foregut endoderm, budding and outgrowth of the liver bud, and hepatoblast differentiation into 
either hepatocytes or biliary epithelial cells (BECs) [41, 215]. In both mice [69, 76] and zebrafish 
[70, 167], inductive signals of Fibroblast Growth Factors (FGFs) and Bone Morphogenetic 
Proteins (BMPs) are essential for hepatoblast specification. In conjunction with the BMP and FGF 
signaling pathways, several homeobox transcription factors, including HHEX and PROX1, also 
regulate the initial stages of liver organogenesis [216]. HHEX regulates hepatoblast proliferation 
and delamination from the foregut endoderm as Hhex−/− mice lack a liver bud and the hepatoblasts 
fail to migrate into the surrounding septum transverse mesenchyme [85]. PROX1 also regulates 
hepatoblast delamination from the liver diverticulum as hepatoblasts fail to migrate 
in Prox1−/− mice [89]. Hepatocyte metabolic gene expression is altered in favor of biliary gene 
expression when Prox1 is ablated in post-delaminated hepatoblasts [90]. hhex [63] 
and prox1a also regulate liver development in zebrafish. prox1a, specifically, marks the initiation 
of hepatoblast specification in zebrafish [28]. Besides HHEX and PROX1, zebrafish and mammals 
share additional transcription factors critical for liver organogenesis, such as GATA6 and hepatic 
nuclear factors (HNFs) [44, 55, 217, 218]. However, a comprehensive understanding of the 
molecular mechanisms underlying transcriptional regulation during liver development still needs 
to be defined.  
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One family of transcriptional regulators essential in developmental processes, including 
cell lineage commitment, proliferation and differentiation, is the helix-loop-helix (HLH) family of 
transcription factors [178, 219]. The HLH domain, essential for dimerization, is important in the 
formation of homo- or hetero-dimers. While some HLH proteins are ubiquitously expressed (e.g., 
E proteins), other HLH proteins are tissue-specific (e.g., PTF1, HES1). HES1, in particular, 
downstream of Notch signaling, is essential for digestive system development, especially in 
extrahepatic bile duct development [220]. In Hes1−/− mice, no tubular structures form in the ductal 
plate during intrahepatic bile duct development [221]. In addition, the bHLH factor, heart and 
neural crest derivatives expressed 2 (Hand2), is expressed in tissues that surround the liver 
primordium, such as the lateral plate mesoderm in zebrafish, which later contributes to the hepatic 
stellate cells [222]. Moreover, bHLH-PAS (Per-ARNT-Sim) factors, such as the hypoxia inducible 
factors (HIFs), participate in hepatic disease, regeneration, fibrosis, and hepatocellular carcinoma 
[223]. Hif2α (renamed as Epas1b) binds hypoxia response elements (HREs) and regulates hepatic 
outgrowth in zebrafish [224]. The activity of bHLH factors can be regulated by the inhibitor of 
DNA binding (ID) family of proteins. 
ID proteins lack the basic DNA binding domain and regulate HLH 
factors via heterodimerization and subsequent creation of nonfunctional, dominant negative 
complexes that lack DNA-binding capability [171]. By heterodimerizing and sequestering 
ubiquitously expressed HLH factors, such as E-proteins (E47, E2-2, HEB, E12), or tissue-
restricted HLH factors, ID proteins can thereby regulate cell proliferation, differentiation and 
apoptosis in a cell-context dependent manner [225]. In the pancreas, for instance, by binding and 
sequestering NeuroD, a bHLH factor implicated in pancreatic beta cell survival and differentiation, 
ID2 regulates pancreatic progenitor expansion [226]. Non-bHLH factors can also bind and 
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regulate ID protein function. For example, hypophosphorylated Retinoblastoma (Rb) tumor-
suppressor protein interacts with ID2 during cell cycle arrest, preventing the latter from 
sequestering other transcription factors and consequently allows differentiation to occur [182, 
190]. Mice with a genetic deletion of Id2 display a reduced number of natural killer cells, lack 
lymph nodes and experience 25% neonatal lethality [227]. To date, no study has examined the role 
of ID2 in hepatogenesis. 
2.2 RESULTS 
2.2.1 id2a Expression in the Developing Liver 
Using whole-mount in situ hybridization (WISH), we examined id2a expression during liver 
development in detail. We first detected id2a expression in the liver-forming region from 30 hours 
post fertilization (hpf) (Figure 6A), when hepatoblast specification has already occurred. At this 
stage, the liver tissue consists of hepatoblasts, which are liver progenitor cells, capable of 
differentiating into either hepatocytes or BECs. Following hepatoblast differentiation, around 72 
hpf, we noted that id2a expression displayed a branching pattern in the liver, indicative of the 
intrahepatic biliary network consisting of BECs. The BEC-specific expression was maintained 
even at 5 days post fertilization (dpf) (Figure 6A). To confirm id2a expression in BECs, we 
conducted immunostaining in conjunction with WISH utilizing 
the Tg(prox1a:YFP), Tg(Tp1:GFP), and Tg(kdrl:GFP) lines, which express fluorescent proteins in 
hepatoblasts [228], BECs [24], and liver endothelial cells [229], respectively. As initially 
observed, id2a was specifically detected in prox1a:YFP-positive (Figure 6B) and Tp1:GFP-
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positive cells (Figure 6C), but not in the endothelial cells (Figure 6D), indicating that in the 
liver, id2a is initially expressed in hepatoblasts and later restricted to BECs. 
 
 
Figure 6: id2a expression in the developing liver  
(A) WISH reveals id2a expression in the liver-forming region at 30 hpf (arrow) and in the liver at 48 hpf 
(arrow), 72 hpf and 5 dpf (dotted lines). From 72 hpf to, at least, 5 dpf, id2a expression in the liver 
appears to be restricted to BECs. Arrowhead points to the interrenal primordium; bracket denotes the 
intestinal bulb. Dorsal (30–72 hpf) or lateral (5 dpf) views, anterior to the left. (B–D) id2a in 
situ hybridization (red) combined with anti-GFP immunostaining (green) in Tg(prox1a:YFP) 
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(B), Tg(Tp1:GFP) (C), or Tg(kdrl:GFP) (D) embryos reveals id2a expression in hepatoblasts at 36 hpf 
and BECs at 60 and 72 hpf, but not in the endothelial cells of the liver (dotted line), respectively. 
Asterisks mark id2a expression in the intestinal bulb. Single confocal section (B) or projections of z-
stack confocal sections (C, D). Scale bars: 100 (A), 20 (B–D) μm.   
 
 
Since the zebrafish genome contains five id genes, we further investigated the expression 
patterns of the remaining four id genes, id1, id2b, id3, and id4, in the liver during embryonic 
development. At 30 hpf, id2b, id3, and id4 are not expressed in the liver-forming region; however, 
it was not clear whether id1 is expressed in the liver-forming region due to its broad expression 
(Figure 7A). Double labeling of id1 and sox17:GFP, which labels all endodermal cells [230], 
showed id1 expression in the liver-forming region (Figure 7E; brackets). At 48 hpf, none of the 
four genes are expressed in the liver. At 72 hpf, id2b, and id3, but not id1 or id4, are expressed in 
the liver (Figure 7B and C; arrows); however, their expression does not mimic the biliary branching 
pattern of id2a expression. Altogether, these expression data indicate that both id1 and id2a are 
expressed in the liver-forming region at 30 hpf and that only id2a expression is restricted to BECs. 
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Figure 7: The expression patterns of id1, id2a, id2b, id3 and id4 during liver development in  
                 zebrafish 
(A-D) Wild-type embryos were processed for WISH analysis with id1 (A), id2b (B), id3 (C), 
and id4 (D) probes. id1 appears to be ubiquitously expressed at 30 hpf, but its expression is absent in the 
liver at 48 and 72 hpf. id2b and id3 expression in the liver was detected at 72 hpf (arrows), but not at 30 
or 48 hpf. id4 is not expressed in the liver. Dorsal views, anterior to the left. (E) id1 in situ hybridization 
(red), combined with anti-GFP immunostaining (green), in Tg(sox17:GFP) embryos 
reveals id1 expression in the liver-forming region (brackets), but not in the dorsal pancreas (dotted lines) 
at 30 hpf. Single confocal optical section, ventral view, anterior up. Scale bars: 100 (A–D), 20 (E) μm. 
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2.2.2 id2a Knockdown Causes an Intrahepatic Biliary Network Deficit in the Developing 
Liver 
Given the restricted expression pattern of id2a in BECs, we sought to determine whether id2a is 
important for intrahepatic biliary development. We conducted loss-of-function analyses using 
published id2a morpholino oligonucleotides (MO) [193, 231, 232]. Consistent with previous 
reports, id2a MO-injected embryos were microcephalic and microphthalmic [193], a 
phenotype also observed in Id2−/− mice [227]. Importantly, the small liver phenotype observed 
in id2a MO-injected embryos was partially rescued by id2a mRNA injection (Figure 8A and 8B), 
further validating the id2a MO. Since id2a is expressed specifically in BECs at later stages of liver 
development, we used the Tg(Tp1:GFP) line to examine BECs.  
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Figure 8: id2a mRNA, but not tp53 MO, injection rescues the reduced liver size in id2a MO-injected  
         embryos 
(A, B) Epifluorescence images showing fabp10a:dsRed expression (red) in control, id2a MO-injected, 
and id2a MO + mRNA-co-injected embryos (A) and their quantification (B). Although the liver of the 
co-injected embryos was still smaller than the control liver, it was much larger than the liver of the single 
MO-injected embryos, indicating a partial rescue of the liver size defect exhibited in id2a MO-injected 
embryos. For quantification, embryos were divided into three groups based on liver size: small, medium, 
and large. The id2a MO-injected liver size shown in A was considered as small; the liver size of the co-
injected embryo shown in A was considered as large. Dorsal view, anterior to the left. (C) Bright-field 
and epifluorescence images showing the overall morphology of embryos and fabp10a:dsRed expression 
(red), respectively, in control, tp53 MO-injected, id2a MO-injected, and id2a MO + tp53 MO-co-
injected embryos. Liver size as well as eye and head size (arrows) in id2a MO-injected embryos was 
 50 
similar to that in embryos co-injected with id2a and tp53 MOs. (D) Quantification of the results in C. 
For quantification, the liver size of the control embryo shown in C was considered as large and the liver 
size of the id2a MO-injected embryo shown in C was considered as small. Lateral view, anterior to the 
left. (E) Epifluorescence images showing the fabp10a:dsRed expression (red) in control and id2a 
mRNA-injected embryos at 72 hpf. Liver size in id2a-mRNA injected embryos was similar to that of 
control embryos. Lateral view, anterior to the left. Scale bars: 100 µm. 
 
Using epifluorescence microscopy, we detected very few GFP-positive cells in the livers 
of id2a MO-injected embryos (Figure 9A; squares), suggesting BEC number was greatly reduced. 
To further analyze the intrahepatic biliary structure, whole-mount immunostaining combined 
with confocal microscopy was used. In id2a MO-injected embryos, not only was the liver size 
reduced, but the intrahepatic biliary network failed to branch, appearing aggregated (Figure 9B). 
Taken together, these data imply that lack of id2a results in defective biliary structure and reduced 
BEC number, suggesting that id2a may regulate intrahepatic biliary development. 
 
2.2.3 id2a Knockdown Reduces Liver Size but does not Block Hepatoblast Specification 
or Hepatocyte Differentiation  
The main steps of liver development include hepatic competence, hepatoblast specification, 
hepatocyte or BEC differentiation, and hepatic outgrowth [41]. Since id2a is expressed in the liver-
forming region from 30 hpf (Figure 6A) after hepatoblast specification, which occurs around 
22 hpf in zebrafish [28], it is unlikely that id2a is implicated in hepatic competence. Thus, we 
examined the expression of the following markers in id2a MO-injected embryos: the early 
hepatoblast markers, hhex and prox1a [28, 233], for hepatoblast specification and maintenance; 
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and the hepatocyte markers, fabp10a, cp, and sepp1b, for hepatocyte differentiation and hepatic 
outgrowth. hhex and prox1a expression was detected in the livers of the MO-injected embryos at 
36 hpf (Figure 9C and D, arrows), suggesting that id2a does not regulate hepatoblast specification 
or its maintenance (Figure 9C and D, arrows).  
Hepatic fabp10a, cp, and sepp1b expression was also detected in the MO-injected embryos 
at 48 hpf (Figure 9E–G, arrows), suggesting that id2a does not regulate hepatocyte differentiation. 
However, the liver size was reduced following id2a knockdown, implicating id2a in regulating 
hepatic outgrowth. Additionally, since id2a is expressed strongly in the gut and intestinal regions 
during development (Figure 6A; bracket), we examined the expression of cdx1b, an intestinal bulb 
marker [234], expecting a similar outgrowth phenotype as observed in the liver. As expected, lack 
of id2a had no effect on cdx1b induction; however, the intestinal bulb failed to grow at 48 hpf 
in id2a MO-injected embryos (Figure 9H, brackets), indicative of an intestinal outgrowth defect. 
We further sought to determine whether id2a knockdown resulted in a general outgrowth defect 
of all endoderm-derived organs or specific organs in which id2a is expressed. Since id2a is not 
expressed in the dorsal pancreas (Figure 6A and 10A), we performed WISH to examine the 
expression of insulin, which marks the pancreatic beta cells of the dorsal pancreas [235]. We found 
no difference in the size of the dorsal pancreas between control and id2a MO-injected embryos 
(Figure 10B).  
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Figure 9: id2a knockdown reduces liver size but does not block hepatoblast specification or  
                 hepatocyte differentiation 
(A) Epifluorescence images revealing a decreased number of Tp1:GFP+ BECs in the liver of id2a MO-
injected embryos at 72 hpf compared with controls (squares). Higher magnification images of the square 
regions are shown in insets. Lateral view, anterior to the left. (B) Confocal projection images revealing 
fabp10a:dsRed (hepatocytes; red), Tp1:GFP (BECs; green) and Anxa4 (the hepatopancreatic ductal 
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system; blue) expression [236]. In id2a MO-injected embryos, liver size was greatly reduced and 
intrahepatic BECs appeared aggregated, displaying a branching defect. (C-H) id2a MO-injected and 
uninjected control embryos were processed for WISH with hhex (C), prox1a (D), fabp10a (E), cp (F), 
sepp1b (G), and cdx1b (H) probes. Overall liver size was greatly reduced in id2a MO-injected embryos 
as revealed by the hepatoblast markers (hhex and prox1a) and the hepatocyte markers (fabp10a, cp, 
and sepp1b). However, the expression of these genes was clearly detected in the MO-injected embryos 
(C–G, arrows), indicating unaltered hepatoblast specification and hepatocyte differentiation 
upon id2a knockdown. The induction of the intestinal bulb as assessed by cdx1b expression appeared 
unaffected in id2a MO-injected embryos at 36 hpf; however, the intestinal bulb failed to grow at 48 hpf 
(H, brackets). The percentage of id2a MO-injected embryos exhibiting the representative 
phenotype shown is indicated in the upper left corner (n = 10–20). The remaining percentage of embryos 
exhibited an intermediate liver/intestinal bulb phenotype: their liver/intestinal bulb size was still smaller 
than that of the control embryos. Arrows point to the liver. Scale bar: 250 (A), 20 (B), and 100 (C–H) 
μm. 
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Figure 10: id2a knockdown does not result in a general endoderm-derived organ defect 
(A) id2a in situ hybridization (red) combined with anti-GFP immunostaining (green) in Tg(sox17:GFP) 
embryos reveals that id2a is highly expressed in the interrenal primordium but not in the dorsal pancreas 
(dashed lines) at 30 hpf. Single confocal section images. (B) id2a MO-injected and control embryos 
were processed for WISH with the insulin probe, which marks pancreatic β-cells of the dorsal pancreas 
(arrows). Overall size of the dorsal pancreas appeared unaffected in the MO-injected embryos compared 
to controls. The percentage of id2a MO-injected embryos exhibiting the representative phenotype shown 
is indicated in the upper left corner (n=10-20). The remaining percentage of embryos exhibited an 
intermediate or slightly larger dorsal pancreas phenotype. Arrows point to the dorsal pancreas. Scale 
bars: 20 µm (A) and 100 µm (B). 
 
Previous studies have implicated ID proteins in the maintenance of neural stem 
cells. Id1 and Id3 double-knockout mice exhibit precocious neuronal differentiation, 
whereas ID2 overexpression in the chick hindbrain inhibits neuronal differentiation [237]. Thus, 
it is still possible that id2a knockdown may result in precocious hepatocyte differentiation. To test 
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this possibility, we examined fabp10a expression at 36 hpf, when fabp10a expression is not yet 
detected in the livers of wild-type embryos. However, fabp10a expression was not detected 
in id2a MO-injected embryos (data not shown), ruling out this possibility. Moreover, we examined 
whether Id2a overexpression could increase liver size. However, liver size was not further 
increased in id2a mRNA-injected embryos at 72 hpf compared with controls (Figure 8E), 
indicating that Id2a is not sufficient for liver outgrowth. 
Altogether, these data indicate that during liver development, id2a is not required for 
hepatoblast specification or hepatocyte differentiation, but rather for hepatic outgrowth. Moreover, 
the outgrowth defect observed in id2a MO-injected embryos may also apply to the development 
of other organ systems, such as the intestinal bulb. 
  
2.2.4 id2a Knockdown Reduces Liver Size via Decreased Hepatoblast Proliferation and 
Increased Cell Death 
To determine whether the small liver observed in id2a MO-injected embryos was caused by 
reduced proliferation and/or enhanced cell death, we conducted anti-phospho-Histone 3 (pH3) 
immunostaining and EdU labeling for proliferation and TUNEL labeling for cell death. Although 
the percentage of pH3+ cells among prox1a:YFP+ hepatic cells in id2a MO-injected embryos at 
40 hpf was not significantly different from that in controls, there was a trend of reduced pH3+ cell 
number in the MO-injected liver compared to the control liver (0–3 versus 3–5) (Figure 11A and 
B). EdU labeling revealed about a 40% decrease in the percentage of EdU+ cells 
among sox17:GFP+ hepatic cells in id2a MO-injected embryos at 40 hpf compared with controls 
(Figure 11C and D), indicating reduced proliferation. In addition, we observed TUNEL 
 56 
and Prox1 double-positive cells in id2a MO-injected embryos at 40 hpf, but not in controls 
(Figure 11E and F). MO-mediated knockdown can often induce apoptosis mediated via aberrant 
p53 activation; thus, concurrent knockdown of tp53 can ameliorate apoptosis induced by MO off-
targeting [238]. Therefore, we performed simultaneous knockdown of tp53 and id2a. We did not 
detect any differences in microphthalmic, microcephalic, or small liver phenotypes between 
single id2a and double id2a/tp53 MO-injected embryos at 60 hpf (Figure 8C and 8D), indicating 
that id2a knockdown phenotypes are independent of the p53 pathway. Altogether, these data 
indicate that id2a regulates hepatic outgrowth by promoting hepatoblast proliferation and 
repressing cell death. 
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Figure 11: id2a knockdown decreases hepatoblast proliferation and increases cell death in the  
                   developing liver 
(A) Whole-mount immunostaining with anti-pH3 (red) anti-GFP (green) antibodies in Tg(prox1a:YFP) 
embryos. The total number of prox1a:YFP+ hepatic cells per liver is 316 ± 8.5 in controls and 156 ± 5.6 
in id2a MO-injected embryos. (B) A graph showing the percentage of pH3+ cells 
among prox1a:YFP+ hepatic cells (n = 10). (C) EdU labeling (red), combined with anti-GFP 
immunostaining (green), in Tg(sox17:GFP) embryos reveals a significant reduction of proliferation in 
the liver of id2a MO-injected embryos at 40 hpf compared with controls. Dotted lines outline the liver. 
 58 
The total number of sox17:GFP+ cells per liver is 220 ± 16.6 in controls and 127 ± 12.7 in id2a MO-
injected embryos. (D) A graph showing the percentage of EdU+ cells among GFP+ hepatoblasts (n = 10). 
(E) TUNEL labeling (red) combined with anti-Prox1 immunostaining (green) reveals apoptosis in the 
liver of id2a MO-injected embryos at 40 hpf, but not in controls. The total number of Prox1+ cells per 
liver is 276 ± 20.5 in controls and 140 ± 8.6 in id2a MO-injected embryos. (F) A graph showing the 
percentage of TUNEL+ cells among Prox1+ hepatoblasts (n = 10). *p < 0.05, **p < 0.005; error bars, ± 
s.e.m. Scale bars: 50 μm. 
2.3 METHODS 
2.3.1 Zebrafish Maintenance 
Embryos and adult zebrafish (Danio rerio) were raised and maintained under standard laboratory 
conditions [239] with protocols approved by the University of Pittsburgh IACUC. 
2.3.2 Zebrafish Strains 
We used the following transgenic lines: TgBAC(prox1a:Citrine)hu338 [228] [referred to 
as Tg(prox1a:YFP)], Tg(EPV.Tp1-Mmu.Hbb:EGFP)um14 [24] [referred to 
as Tg(Tp1:GFP)], Tg(kdrl:EGFP)s843 [229] [referred to as Tg(kdrl:GFP)], Tg(ptf1a:EGFP)jh1 [240] 
[referred to as Tg(ptf1a:GFP)], Tg(sox17:GFP)s870 [230] 
and Tg(fabp10a:dsRed,ela31:GFP)gz12 [39] [referred to as Tg(fabp10a:dsRed)]. 
 59 
2.3.3 Morpholino and mRNA Injections 
id2a MO (5′-GCCTTCATGTTGACAGCAGGATTTC-3′) [193] and tp53 MO (5′-
GCGCCATTGCTTTGCAAGAATTG-3′) [241] were purchased from GeneTools (Philomath, 
OR, USA). 3–4 ng of id2a MO or 2 ng of tp53 MO was injected into one-cell stage embryos. For 
rescue experiments, 3 ng of the id2a MO and 150 pg of id2a mRNA, which is resistant to 
the id2a MO, was sequentially injected into one-cell stage embryos. The id2a mRNA was 
generated using the mMessage mMachine SP6 kit (Life Technologies, Grand Island, NY, USA). 
2.3.4 Whole-mount In Situ Hybridization and Immunohistochemistry 
Whole-mount in situ hybridization was performed as previously described [242]. cDNA from 24-
hpf embryos was used as a template for PCR to amplify id1, id2a, id2b, id3, and id4 genes. We 
also used the following probes: hhex [243], prox1 [244], fabp10a [245], sepp1b [246], cp [64], 
and cdx1b [247]. Whole-mount immunostaining was performed as previously described [29], 
using the following antibodies: chicken polyclonal anti-GFP (1:100; Aves Labs, Tigard, OR, 
USA), rabbit polyclonal anti-Prox1 (1:1000; Millipore, Billerica, MA, USA), 
mouse monoclonal anti-Anxa4 (also named as 2 F11; 1:100; Abcam, Cambridge, MA USA), 
rabbit polyclonal anti-dsRed (1:200; Clontech, Mountain View, CA, USA), mouse monoclonal 
anti-phospho-Histone H3 (1:100; Cell Signaling, Danvers, MA, USA) and conjugated secondary 
antibodies, including Alexa Fluor 405, 488, 568, and 647 (1:300; Life Technologies, Grand Island, 
NY, USA). Hoechst 33342 (2.5 ng/ml; Sigma-Aldrich, St. Louis, MO, USA) was used for DNA 
staining. Zeiss LSM700 was used for confocal microscopy. 
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2.3.5 TUNEL and EdU Assays 
Apoptotic cell death was analyzed according to the protocol of the In Situ Cell Death Detection 
Kit, TMR Red (Roche, Switzerland). Following whole-mount immunostaining, TUNEL labeling 
was applied. Cell Proliferation was performed using the protocol outlined in the Click-iT EdU 
Alexa Fluor 647 Imaging Kit (Life Technologies, Grand Island, NY, USA). Larvae were incubated 
with EdU solution at 39 hpf for one hour, and at 40 hpf, they were harvested for EdU staining. 
Unpaired two-tailed Student's t-tests were used for statistical analysis; p < 0.05 was considered 
statistically significant. 
2.4 DISCUSSION 
In this study, we sought to determine the role of Id2a in liver development. We report three 
important findings. First, by using WISH followed by immunostaining, we discovered that id2a is 
initially expressed in the liver-forming region from 30 hpf and following hepatoblast 
differentiation at 48 hpf, id2a expression is restricted to BECs. Second, id2a knockdown did not 
affect hepatocyte differentiation or hepatoblast specification, which correlates with a lack 
of id2a liver expression during the hepatoblast specification stage (i.e., 22 hpf). Lastly, our data 
revealed that id2a knockdown inhibited hepatic outgrowth during development as supported by 
the reduced liver size in id2a MO-injected embryos. 
Similar to the phenotype observed in id2a MO-injected embryos, in which hepatic 
outgrowth was compromised while hepatoblast specification and hepatocyte differentiation 
appeared unaffected, additional genes are also implicated in regulating hepatic outgrowth in 
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zebrafish. Classified as a tumor suppressor gene that functions as a transcriptional activator, core 
promoter element binding protein (copeb; renamed as klf6a) is expressed in the zebrafish digestive 
organs, including the liver, the pancreas, and intestine. In copeb MO-injected embryos, the 
expansion of the liver is impaired [248]. Moreover, the failure of hepatic outgrowth in copeb MO-
injected larvae is also attributed to a decrease in cell proliferation, as observed in id2a MO-injected 
embryos [248]. A similar phenotype is observed in the cell cycle modulator ubiquitin-like with 
PHD and ring finger domains 1 (uhrf1) mutants, which exhibit smaller livers as a result of a 
proliferation defect during the hepatic outgrowth phase [27]. In addition, knockdown of 
either sfrp5 [249] or nav3a [250] also results in a defect in hepatoblast outgrowth and subsequent 
liver size in 40-hpf zebrafish embryos. These results correlate with the well-known role of ID 
proteins as master regulators of cell proliferation [251], especially evident during early 
development. 
Early development is a process defined by rapid cell proliferation followed by cell 
differentiation, generating distinct, mature tissues. Generally, Id expression is 
usually upregulated during the cell proliferation phase of early tissue development, and 
subsequently downregulated in mature, differentiated cells [252, 253]. However, exceptions exist; 
therefore, ID protein-mediated proliferation is cell context-dependent. For example, 
overexpression of Id1, Id2, or Id3 in neural stem cells derived from the mouse 
embryonic forebrain maintains the cortical neural stem cells in a proliferative, self-renewing state, 
and simultaneously inhibits neuronal differentiation [254]. In contrast, upon differentiation 
of hematopoietic progenitor cells, Id2 expression increases [255]. Previously, Uribe et al. reported 
on the role of id2a in zebrafish retinogenesis. Upon id2a knockdown, proliferative retinoblasts (in 
the S-phase) increased as mitotic retinoblasts (in the M-phase) decreased, which demonstrates a 
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role of Id2a in regulating the S- to M-phase progression during the cell cycle [193]. In contrast, 
we noted a significant decrease in the number of proliferating hepatoblasts at 40 hpf in id2a MO-
injected embryos. As aforementioned, this phenotypic difference observed in proliferative cells 
during retinogenesis and liver development alludes to the dependence on cellular contexts in 
which id genes were studied. Nonetheless, id2a appears to play an important role in regulating 
proliferation in diverse tissue contexts including the developing liver. 
In addition to proliferation, ID proteins also regulate apoptosis in a cell-dependent manner 
[188, 256]. While apoptosis is significantly increased in mammary epithelial 
cells of Id2−/− pregnant mice [257], overexpression of Id1, Id2, or Id3 induces apoptosis in serum-
deprived rat embryonic fibroblasts [258]. In id2a MO-injected embryos, we observed a significant 
increase in the number of TUNEL-positive hepatoblasts at 40 hpf, highlighting the role of Id2a in 
regulating apoptosis in the developing liver. 
Although intrahepatic biliary defects were also observed in id2a MO-injected embryos, it 
is unclear if the defects are either attributed to (1) a primary phenotype due to id2a knockdown or 
(2) a secondary phenotype due to compromised hepatic outgrowth. BEC-specific knockdown or 
knockout of id2a should conclusively establish a direct or indirect role of id2a in intrahepatic 
biliary morphogenesis. Currently, however, it is a challenge to create such a tool in zebrafish. 
As id2a expression is restricted in BECs during liver development, it will be interesting to explore 
the role of id2a in biliary-driven liver regeneration. Previously, we reported on a novel hepatocyte-
specific genetic ablation model in zebrafish: following severe hepatocyte loss, BECs contribute to 
the repopulation of the liver [20]. Few reports have explored the role of ID2 in liver regeneration. 
In two different models of liver injury in rats, partial hepatectomy and bile duct ligation, Id2 is 
immediately upregulated during the hepatocyte priming phase and ID2 expression is detected in 
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the proliferating hepatocytes, respectively [259]. However, the role of Id2 in liver regeneration has 
not been reported yet. In addition, although ID2 has been shown to interact with various factors, 
including MyoD during myogenesis [260], future analysis should consider the currently unknown 
binding factor of Id2a in the developing zebrafish liver. Since id2a knockdown reduced the liver 
size, we speculate the binding partner of Id2a to function as a suppressor of hepatic outgrowth and 
a negative regulator of hepatoblast proliferation. 
Our findings validate the role of id2a in promoting hepatic outgrowth and development. 
Future studies should explore the mechanism of action of Id2a, including its binding partner, in 
liver development. Discerning the molecular mechanisms regulating liver development will 
improve our comprehension of the biological relevance of hepatic diseases and methods to enhance 
innate liver regeneration. 
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3.0  BMP SIGNALING GOVERNS BILIARY-DRIVEN LIVER REGENERATION IN 
ZEBRAFISH VIA TBX2B AND ID2A 
3.1 BACKGROUND 
As a highly regenerative organ, the liver can undergo either hepatocyte- or biliary-driven 
regeneration.  In the former case, upon partial hepatectomy or mild liver injury, hepatocytes 
proliferate to restore the lost liver mass [112].  However, in the latter case, upon severe liver injury 
in which hepatocyte proliferation is compromised, biliary epithelial cells (BECs) dedifferentiate 
into liver progenitor cells (LPCs), also called oval cells or hepatoblast-like cells (HB-LCs), and 
subsequently give rise to hepatocytes [261].  Previously, controversies existed regarding the 
relative contribution of BEC-driven liver regeneration [262]; however, recent studies in zebrafish 
[20, 132] and mice [263] have resolved this controversy by showing the extensive contribution of 
BECs to hepatocytes upon severe liver injury.  In mice, hepatocyte-specific Mdm2 deletion 
completely blocks hepatocyte proliferation, additionally induces hepatocyte senescence and 
apoptosis, and subsequently elicits oval cell activation.  These oval cells later give rise to 
hepatocytes, leading to a full liver recovery [263].  In the zebrafish studies, the near-complete 
ablation of hepatocytes elicits the extensive contribution of BECs to hepatocytes through the 
dedifferentiation of BECs into HB-LCs and subsequent differentiation of the HB-LCs into 
hepatocytes [20, 132]. 
Oval cells are frequently observed in diseased livers and their number positively correlates 
with disease severity [264].  Since patients suffering from severe liver diseases have limited 
treatment options and present with an abundance of hepatic oval cells, promoting the 
 65 
differentiation of oval cells into hepatocytes is deemed an effective therapeutic strategy.  
Developing such therapies requires a deeper understanding of the mechanisms by which oval cells 
differentiate into hepatocytes in vivo.  Although several factors, such as FGF7 [139] and TWEAK 
[265], which can induce oval cell activation in vivo, have been identified, factors that regulate oval 
cell differentiation into hepatocytes in vivo are unknown, mainly due to the lack of an animal 
model for BEC-driven liver regeneration.  However, the recent reports of zebrafish and mouse 
liver injury models, in which BECs extensively contribute to regenerated hepatocytes, present an 
opportunity to investigate the mechanisms underlying oval cell differentiation into hepatocytes. 
Using the zebrafish BEC-driven liver regeneration model combined with targeted chemical 
screening, we recently reported on the role of bromodomain extraterminal (BET) proteins in BEC 
dedifferentiation into HB-LCs and the proliferation of newly-generated hepatocytes [266].  Using 
the same zebrafish model, we now show the essential role of Bmp signaling in HB-LC 
differentiation into hepatocytes.  Bmp signaling plays important roles in early liver development, 
such as hepatoblast specification and proliferation [70, 76].  Despite its clear role in early liver 
development, the role of Bmp signaling in liver regeneration has not been clearly defined.  Current 
literature provides confounding results that BMP2 [267] and BMP4 [169] negatively while BMP7 
[268] positively regulate hepatocyte-driven liver regeneration after partial hepatectomy in rodents.  
Moreover, there is no report on the role of Bmp signaling in BEC-driven liver regeneration.  Given 
the important role of Bmp signaling in early liver development and its positive effect on 
regeneration of other organs, including the heart [269], we hypothesized that Bmp signaling might 
regulate BEC-driven liver regeneration.  Our finding that the hepatic expression of several genes 
implicated in Bmp signaling, including smad5, was upregulated during BEC-driven liver 
regeneration further supported our hypothesis.  In this study, we report that Bmp signaling 
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regulates two distinct steps of BEC-driven liver regeneration: (1) HB-LC differentiation into 
hepatocytes, and (2) the proliferation of newly-generated BECs. 
3.2 RESULTS 
3.2.1 BMP Signaling is Required for BEC-driven Liver Regeneration 
We have established a zebrafish liver injury model in which BECs extensively contribute to 
hepatocytes [20].  Specifically, Tg(fabp10a:CFP-NTR) fish express nitroreductase (NTR) under 
the hepatocyte-specific fabp10a promoter; the treatment of metronidazole (Mtz), which is 
converted into a cytotoxic drug by NTR, results in hepatocyte-specific ablation in the transgenic 
fish.  In this model, severe hepatocyte ablation induces the dedifferentiation of BECs into HB-
LCs, which then differentiate into hepatocytes, thereby leading to a full liver recovery.  To 
understand the molecular mechanisms underlying BEC-driven liver regeneration, we performed 
RNAseq analyses and compared gene expression profiles between control and regenerating livers 
at multiple time points during the regeneration. Through this analysis and subsequent validation 
with RT-PCR and whole-mount in situ hybridization (WISH) (Figure 12), we found that genes 
implicated in the Bmp signaling pathway, such as smad5, id2a, and tbx2b, were upregulated in 
regenerating livers at regeneration (R) 6h compared with controls (Figure 13A-13C).   
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Figure 12: Validation of RNAseq data using RT-PCR and WISH  
RT-PCR and WISH were performed to validate genes-of-interest from RNAseq analysis.  For RT-PCR, 
cDNA was prepared from control livers at 5 dpf and from Mtz-treated regenerating livers at R6h.  For 
in situ hybridization, control larvae at 5 dpf and regenerating larvae at R6h were used.  Arrows point to 
regenerating livers.  Scale bar: 150 µm. 
 
Bmp signaling plays an essential role in hepatoblast specification and liver growth during 
liver development [70, 76], but its role in liver regeneration has not been clearly defined.  Thus, to 
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determine whether Bmp signaling was required for BEC-driven liver regeneration, we applied the 
selective Bmp inhibitor, DMH1, which has been widely used in zebrafish.  During BEC-driven 
liver regeneration, a hepatoblast/hepatocyte marker, Hnf4a, is induced in BECs and the expression 
of Prox1, a marker for hepatoblasts, hepatocytes, and BECs, is also upregulated in BECs [20].  In 
addition, the expression of Alcam, a good marker of zebrafish BECs [270] is sustained in HB-LCs, 
but disappears from HB-LCs when these cells differentiate into hepatocytes [20].  DMH1 treatment 
from ablation (A) 0h greatly repressed Hnf4a, but not Prox1 or Alcam, expression, at R0h (Figure 
13D).  Intriguingly, DMH1 treatment after hepatocyte ablation (from R0h) significantly increased 
the number of BECs at R30h, as assessed by Alcam and Tp1:H2B-mCherry expression (Figure 
13E).  The Tg(Tp1:H2B-mCherry) line, which expresses stable H2B-mCherry fusion proteins 
under the Tp1 promoter containing the Notch-responsive element, reveals BECs in the liver [271].  
Collectively, these data indicate the essential roles of Bmp signaling in BEC-driven liver 
regeneration. 
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Figure 13: Bmp signaling is required for BEC-driven liver regeneration  
(A, B) RT-PCR (A) and qPCR (B) data showing the expression levels of smad5, id2a and tbx2b between 
control and regenerating livers at R6h.  (C) WISH images showing the expression of smad5, id2a and 
tbx2b in control (dashed lines) and regenerating (arrows) livers.  Numbers indicate the proportion of 
larvae exhibiting the expression shown.  (D) Single-optical section images showing the expression of 
Hnf4a and Prox1 or Alcam in regenerating livers.  (E) Confocal projection images showing Tp1:H2B-
mCherry and Alcam expression in regenerating livers.  Quantification of the number of H2B-
mCherry/Alcam double-positive cells (i.e., BECs).  Scale bars: 150 (C), 20 (D, E) µm; error bars: ±SEM. 
3.2.2 Inhibition of BMP Signaling Blocks HB-LCs Differentiation into Hepatocytes 
Next, we investigated in detail the effect of Bmp inhibition on earlier stages of BEC-driven liver 
regeneration.  We first determined if Bmp inhibition blocked the dedifferentiation of BECs into 
HB-LCs.  By examining Hnf4a expression at various time points between A24h and A36h, we 
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found that Hnf4a induction in BECs occurred around A33h and that its expression became 
stronger at A36h (Figure 14A, arrows).  As Hnf4a induction in BECs is indicative of BEC 
dedifferentiation [20], these data suggest that BECs dedifferentiate into HB-LCs around A33h.  
This observation was further supported by the expression of fabp10a:rasGFP (Figure 14B), 
which is not expressed in hepatoblasts during liver development but induced in BECs during 
BEC-driven liver regeneration [266].  At A33h, there were fabp10a:rasGFP+ cells negative for 
Hnf4a (Figure 14C, arrows), but not vice versa, indicating that fabp10a induction in BECs 
precedes Hnf4a induction.  Although Hnf4a expression in BEC-derived cells was greatly reduced 
at A36h in DMH1-treated regenerating livers compared with their controls (Figure 13D), the 
initial induction of Hnf4a and fabp10a:rasGFP in BECs at A33h in DMH1-treated regenerating 
livers occurred similarly to DMSO-treated controls (Figures 14A and 14B).  These data together 
with the Prox1 expression in HB-LCs indicate that Bmp inhibition does not block the 
dedifferentiation of BECs.    
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Figure 14: Inhibition of Bmp signaling does not block BEC dedifferentiation into HB-LCs 
(A) Single-optical section images showing Hnf4a (green) and Tp1:H2B-mCherry (red) expression in 
ablating livers of DMH1- or DMSO-treated larvae at A24h, A30h, A33h and A36h.  Arrows point to 
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Hnf4a+/H2B-mCherry+ cells.  (B) Single-optical section images showing fabp10a:rasGFP (green) and 
Tp1:H2B-mCherry (red) expression in ablating livers at A33h and A36h.  (C) Single-optical section 
images showing the expression of fabp10a:rasGFP (green), Hnf4a (gray), and Tp1:H2B-mCherry (red) 
in ablating livers at A33h.  Arrows point to rasGFP+/Hnf4a+/H2B-mCherry+ cells; arrowheads point to 
rasGFP+/Hnf4a-/H2B-mCherry+ cells.  Scale bars: 20 µm. 
 
Given that Hnf4a is the master regulator of hepatocyte differentiation [216], the reduced 
Hnf4a expression upon Bmp inhibition (Figure 13D) suggests a role for Bmp signaling in HB-LC 
differentiation into hepatocytes.  To address this possibility, we sought to examine DMH1-treated 
regenerating larvae at later stages, such as R24h.  However, the continuous DMH1 treatment from 
A0h killed most regenerating larvae before R24h, preventing the examination of the regenerating 
livers at later stages. By treating ablating larvae with DMH1 from different time points, we found 
that DMH1 treatment from A33h also reduced Hnf4a expression at R6h (Figure 15A) but did not 
kill regenerating larvae as late as R24h.  At R24h, A33h DMH1-treated regenerating livers 
exhibited the following phenotypes: (1) sustained Alcam expression in most BEC-derived 
Tp1:H2B-mCherry+ cells, not just in BECs (Figure 15B); (2) sustained Notch activity throughout 
regenerating livers (Figure 15C); and (3) no expression of hepatocyte markers, Bhmt, cp, and gc 
(Figures 15D and 15E), indicating a defect in HB-LC differentiation into hepatocytes.  Despite a 
lack of hepatocyte marker expression, genes expressed in hepatoblasts, such as foxa3 and prox1a, 
were expressed similarly in DMSO- and DMH1-treated regenerating livers (Figure 15E).  fabp10a, 
which is expressed in HB-LCs (Figure 14B), was also normally expressed (Figures 15D and 15E).  
In addition to the pharmacologic inhibition, we blocked Bmp signaling using the Tg(hs:dnBmpr1) 
line that expresses dominant-negative Bmpr1 under the hsp70l heat-shock promoter.  The 
overexpression of dnBmpr1 via a single heat-shock at A30h resulted in sustained Notch activity 
 73 
and reduced Hnf4a expression in regenerating livers at R12h (Figure 15F).  All these data indicate 
the role of Bmp signaling in HB-LC differentiation into hepatocytes. 
 
 
Figure 15: Bmp inhibition blocks HB-LC differentiation into hepatocytes 
(A) Single-optical section images showing Hnf4a and Tp1:H2B-mCherry expression in regenerating 
livers.  To quantify Hnf4a expression, BEC-derived H2B-mCherry+ cells were divided into three cases: 
Hnf4astrong (arrows), Hnf4aweak (arrowheads), and Hnf4aabsent (open arrows).  Quantification of the 
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percentage of these three cell types among H2B-mCherry+ cells.  (B) Single-optical section images 
showing Alcam and Tp1:H2B-mCherry expression in regenerating livers.  In DMH1-treated 
regenerating livers, Alcam was expressed in both H2B-mCherrystrong (arrows) and H2B-mCherryweak 
cells (arrowheads), whereas in control regenerating livers, Alcam was expressed only in H2B-
mCherrystrong cells.  Quantification of the percentage of Alcam+ cells among H2B-mCherry+ cells.  (C) 
Single-optical section images showing the expression of Tp1:VenusPEST and Tp1:H2B-mCherry in 
regenerating livers.  Quantification of the percentage of VenusPEST+ cells among H2B-mCherry+ cells.  
(D) Single-optical section images showing Bhmt and fabp10a:rasGFP expression in regenerating livers.  
Quantification of the percentage of Bhmt+ cells among BEC-derived fabp10a:rasGFP+ cells.  (E) WISH 
images showing the expression of fabp10a, foxa3, prox1a, cp and gc in regenerating livers (arrows).  (F) 
Single-optical section images showing Hnf4a, Tp1:VenusPEST, and Tp1:H2B-mCherry expression in 
regenerating livers.  The Tg(hs:dnBmpr1-GFP) line was used to block Bmp signaling via a single heat-
shock at A30h.  Quantification of the percentage of Hnf4astrong (arrows), Hnf4aweak (arrowheads), and 
Hnf4aabsent (open arrows) cells and of VenusPEST+ cells among H2B-mCherry+ cells.  Scale bars: 20 (A-
D, F), 150 (E) µm; error bars: ±SEM. 
3.2.3 Inhibition of BMP Signaling Maintains HB-LCs in their Undifferentiated State 
Based on sustained Notch activity and Alcam expression in A33h DMH1-treated regenerating 
livers, we hypothesized that HB-LCs that failed to differentiate into hepatocytes remained as 
undifferentiated HB-LCs in DMH1-treated regenerating livers.  To test this hypothesis, we used 
Cre/loxP-mediated lineage tracing and determined the lineages of HB-LCs.  To label HB-LCs, we 
used two Cre lines, Tg(Tp1:CreERT2) that expresses CreERT2 under the Tp1 promoter and 
Tg(fabp10a:CreERT2) that expresses CreERT2 under the fabp10a promoter [20].  Since Notch 
activity is strong in BECs but weak in HB-LCs, the former line labels most BECs but a few HB-
LCs.  Likewise, since fabp10a expression is strong in hepatocytes but weak in HB-LCs, the latter 
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line labels most hepatocytes but a few HB-LCs.  When Tp1:CreERT2 and fabp10a:CreERT2 were 
activated by tamoxifen (4-OHT) treatment from A33h to R6h, 95% of BECs and 96% of 
hepatocytes, respectively, were labeled at R54h (Figure 16B).  However, few hepatocytes were 
labeled by the Tp1:CreERT2 activation (Figure 16C) and few BECs were labeled by the 
fabp10a:CreERT2 activation (Figure 16D), indicating that few HB-LCs were labeled in these Cre 
activation settings.  This low efficiency of HB-LC labeling can be explained by the weak Notch 
activity and weak fabp10a expression in HB-LCs and the short duration of HB-LCs in the zebrafish 
liver injury model.  If the HB-LCs fail to differentiate and remain in a progenitor-like state, more 
HB-LCs will be labeled in the Cre activation settings, thereby more hepatocytes and BECs were 
labeled by Tp1:CreERT2 and fabp10a:CreERT2, respectively.  We observed these phenomena in 
regenerating livers treated with DMH1 from A33h to R6h (Figures 16C and 16D), strongly 
suggesting that Bmp inhibition maintains HB-LCs in their undifferentiated state. 
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Figure 16: Bmp inhibition maintains HB-LCs in an undifferentiated state 
(A) Experimental scheme illustrating the stages of Mtz, DMH1, and 4-OHT treatment.  (B) Labeling 
efficiency of the lineage tracing with the Tg(Tp1:CreERT2) and Tg(fabp10a:CreERT2) lines.  Arrows 
point to CFP-/mCherry+/Alcam+ cells (Cre-labeled BECs); arrowheads point to CFP+/mCherry+/Alcam- 
cells (Cre-labeled hepatocytes).  Quantification of the percentage of the labeled BECs and hepatocytes.  
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(C, D) Single-optical section images showing the expression of mCherry, Alcam, and fabp10a:CFP-
NTR in regenerating livers at R54h.  A Cre reporter line, Tg(ubb:loxP-GFP-loxP-mCherry), was used 
together with the Tg(Tp1:CreERT2) (C) or the Tg(fabp10a:CreERT2) (D) line.  Arrows point to 
CFP+/mCherry+/Alcam- hepatocytes; arrowheads point to CFP-/mCherry+/Alcam+ BECs.  Quantification 
of the numbers of CFP+/mCherry+/Alcam- hepatocytes and CFP-/mCherry+/Alcam+ BECs per liver.  
Scale bars: 20 µm; error bars: ±SEM. 
3.2.4 Inhibition of BMP Signaling After Hepatocyte Ablation Increases BEC Number in 
Regenerating Livers via Proliferation 
Unlike its treatment from A33h, DMH1 treatment from R0h did not affect HB-LC differentiation 
into hepatocytes, as assessed by cp and gc expression (Figure 17).   
 
 
Figure 17: Inhibition of Bmp signaling after hepatocyte ablation does not affect HB-LC  
    differentiation into hepatocytes 
WISH images showing the expression of foxa3, prox1a, fabp10a, cp and gc in regenerating livers 
(arrows) at R30h.  Numbers in the upper right corner indicate the proportion of larvae exhibiting the 
representative expression shown.  Scale bar, 150 µm. 
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Given the increased number of BECs upon DMH1 treatment from R0h (Figure 13E), we 
determined the latest time point from which DMH1 treatment still increased BEC number.  We 
found that DMH1 treatment from R12h, but not R24h, significantly increased BEC number (Figure 
18A).  Using a cell-cycle reporter line, Tg(Tp1:mAGFP-gmnn), which reveals BECs in the S/G2/M 
(but not G0/G1) phases of the cell cycle, we observed that BEC proliferation was significantly 
increased in DMH1-treated regenerating livers at R30h compared with their controls (Figure 18B).  
In addition to the chemical inhibition of Bmp signaling, the overexpression of dnBmpr1 via a 
single heat-shock at R8h increased BEC proliferation in regenerating livers at R30h (Figures 18C 
and 18D).  Altogether, these data indicate that Bmp signaling controls the number of BECs in 
regenerating livers by temporarily suppressing their proliferation. 
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Figure 18: Bmp inhibition after hepatocyte ablation increases BEC number in regenerating livers via  
    proliferation   
(A) Experimental scheme illustrating the stages of Mtz and DMH1 treatment.  Quantification of the total 
numbers of BECs in regenerating livers treated with DMH1 for three different time-windows.  (B) 
Confocal projection images showing Tp1:H2B-mCherry and Tp1:mAGFP-gmnn expression in 
regenerating livers.  Arrows point to mCherry/mAGFP-gmnn double-positive cells.  Quantification of 
the percentage of mAGFP-gmnn+ cells among H2B-mCherry+ BECs.  (C) Confocal projection images 
showing the expression of Alcam, Tp1:H2B-mCherry, and fabp10a:CFP-NTR in regenerating livers at 
R30h.  Quantification of the total numbers of BECs (H2B-mCherry+/Alcam+) per liver.  (D) Confocal 
projection images showing EdU labeling and Alcam and Tp1:H2B-mCherry expression in regenerating 
livers.  Arrows point to EdU+ BECs.  Quantification of the percentage of EdU+ cells among BECs.  Scale 
bars: 20 µm; error bars: ±SEM. 
3.2.5 smad5 Mutants Exhibit a Defect in HB-LC Differentiation into Hepatocytes 
Given the upregulation of genes implicated in Bmp signaling, such as smad5, tbx2b, and id2a, in 
regenerating livers (Figures 13A-13C), we determined if DMH1 treatment suppressed this 
upregulation.  Indeed, quantitative RT-PCR (qPCR) and WISH showed a reduction of the hepatic 
expression of smad5, tbx2b, and id2a in DMH1-treated regenerating livers at R6h compared with 
their controls (Figure 19A), suggesting a potential role for these genes in mediating Bmp signaling 
during BEC-driven liver regeneration.  To test this possibility, we examined BEC-driven liver 
regeneration in smad5 mutants.  Smad5, together with Smad1 and Smad9, known as receptor-
regulated Smads (R-Smads), relays Bmp signaling from the cell surface to the nucleus [272].  
Zebrafish smad5-/- mutants started to die from 3 dpf but smad5 mRNA injection into one-cell-stage 
embryos increased their survival time [273], allowing for our liver regeneration assay.  Although 
the mRNA-injected mutants had a smaller liver than their siblings, liver development occurred, as 
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observed by their liver growth (Figure 19B) and the branching of the intrahepatic biliary structure 
(Figure 19C).   
 
 
Figure 19: mRNA injection rescues survival of smad5 mutants 
(A) qPCR data showing the relative expression levels of smad5, tbx2b, id2a and hnf4a between DMSO- 
and DMH1-treated regenerating livers at R6h; WISH images showing the expression of smad5, tbx2b 
and id2a in regenerating livers (arrows). (B) Experimental scheme illustrating the stages of smad5 
mRNA injection (red arrow) and analysis (arrows) for C and D.  (C) Single-optical section images 
showing Tp1:VenusPEST and Tp1:H2B-mCherry expression in the livers of smad5-/- mutants and wild-
type siblings at 5 dpf. (D) Epifluorescence images showing hepatic fabp10a:CFP-NTR expression (red) 
in smad5-/- mutants and wild-type siblings at 4, 5, and 6 dpf. Scale bars: 150 (A, D), 20 (C) µm. 
 
Since liver size was smaller in the mRNA-injected mutants than in wild-type, we applied 
Mtz from 5 dpf, when the mutant liver size is similar to that of 3.5-dpf wild-type livers. In this 
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rescue setting, the smad5-/- mutants exhibited sustained Notch activity and Alcam expression 
throughout regenerating livers (Figures 20B-20C) and no cp, but faint gc, expression (Figure 20D) 
at R24h, recapitulating the HB-LC differentiation defects observed in A33h DMH1-treated 
regenerating livers.  The expression of tbx2b and id2a in regenerating livers also appeared to be 
reduced in the smad5-/- mutants compared with their siblings (Figure 20D), further supporting that 
Bmp signaling regulates tbx2b and id2a expression in regenerating livers.   
 
 
Figure 20: smad5 mutants exhibit a defect in HB-LC differentiation into hepatocytes 
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(A) Experimental scheme illustrating the stages of smad5 mRNA injection (red arrow) and Mtz treatment 
for B-D.  (B) Single-optical section images showing Tp1:VenusPEST and Tp1:H2B-mCherry expression 
in regenerating livers.  Quantification of the percentage of VenusPEST+ cells among BEC-derived H2B-
mCherry+ cells.  (C) Single-optical section images showing Alcam and Tp1:H2B-mCherry expression 
in regenerating livers.  Quantification of the percentage of Alcam+ cells among BEC-derived H2B-
mCherry+ cells.  (D) WISH images showing the expression of tbx2b, id2a, cp and gc in regenerating 
livers (arrows).  Scale bars: 150 (D), 20 (B, C) µm; error bars: ±SEM. 
 
When examined at R48h, continuous DMH1 treatment from A33h was fatal for the 
zebrafish larvae recovering from severe liver injury, preventing the analysis of BEC-driven liver 
regeneration at later stages.  However, the smad5-/- mutants recovered at R48h from the initial 
regeneration defects, as displayed by the rapid growth of their regenerating livers (Figure 21B), 
normal Notch activity (Figure 21C), and recovered cp and gc expression (Figure 21D).  Altogether, 
data from smad5 mutant analyses indicate the role of smad5 in BEC-driven liver regeneration. 
 
Figure 21: HB-LC differentiation defect observed in smad5 mutants at R24h recovers at R48h 
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(A) Experimental scheme illustrating the stages of smad5 mRNA injection and Mtz treatment and 
analysis for E-G.  (B) Epifluorescence images showing fabp10a:CFP-NTR expression (red) in the 
regenerating livers of smad5-/- mutants and wild-type siblings at R24h and R48h.  (C) Single-optical 
section images showing the expression of Hnf4a (gray), Tp1:H2B-mCherry (red), Tp1:VenusPEST 
(green), and fabp10a:CFP-NTR (blue) in the regenerating livers of smad5-/- mutants and wild-type 
siblings at R48h.  (D) WISH images showing cp and gc expression in the regenerating livers (arrows) of 
smad5-/- mutants and wild-type siblings at R48h.  Scale bars: 150 (B), 20 (C, D) µm. 
3.2.6 tbx2b Mutants Exhibit a Defect in HB-LC Differentiation into Hepatocytes  
TBX3, a T-box transcription factor, promotes hepatoblast proliferation and maintains the 
expression of HNF4A and CEBPA, two key transcription factors regulating hepatocyte 
differentiation, in hepatoblasts [274].  TBX2, a close homolog of TBX3, is required for the 
development of the heart, pharyngeal arch, and optic cup; importantly, its expression in these 
tissues is regulated by Bmp signaling [275].  Thus, to determine if tbx2b was required for BEC-
driven liver regeneration, we used zebrafish tbx2b mutants because they develop with normal body 
morphology (Figure 22A) and survive long enough for our liver regeneration assay [276].  Despite 
the absence of liver developmental defects (Figure 22B), tbx2b-/- mutants exhibited a defect in HB-
LC differentiation into hepatocytes during BEC-driven liver regeneration.   
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Figure 22: tbx2b mutants still exhibit a defect in HB-LC differentiation into hepatocytes at R48h 
(A) Epifluorescence images showing hepatic fabp10a:CFP-NTR expression (red) in tbx2b-/- mutants and 
wild-type siblings at 5 dpf.  (B) Confocal projection images showing Alcam (green) and Tp1:H2B-
mCherry (red) expression in the uninjured liver of tbx2b-/- mutants and wild-type siblings at 5 dpf.  (C) 
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Single-optical section images showing the expression of Tp1:VenusPEST (green), Tp1:H2B-mCherry 
(red), fabp10a:CFP-NTR (blue), and Hnf4a (gray) in the regenerating livers of tbx2b-/- mutants and their 
siblings at R48h.  (D) Single-optical section images showing the expression of fabp10a:rasGFP (green), 
Tp1:H2B-mCherry (red), and Hnf4a (gray) in the regenerating livers of tbx2b-/- mutants and their siblings 
at R6h.  Quantification of the percentage of Hnf4a+ cells among H2B-mCherry+ BEC-derived cells is 
shown.  Numbers in the upper right corner indicate the proportion of larvae exhibiting the representative 
phenotype shown.  Scale bars: 150 (A), 20 (B-D) µm. 
 
In control regenerating livers, all Tp1:VenusPEST-/Tp1:H2B-mCherry+ cells expressed 
Hnf4a and Bhmt at R24h, indicating that they are hepatocytes derived from BECs.  However, in 
tbx2b-/- regenerating livers, many Tp1:VenusPEST-/Tp1:H2B-mCherry+ cells not only failed to 
express Hnf4a and Bhmt (Figures 23A-23C), but also showed sustained Alcam expression at R24h 
(Figure 23D).  This phenotype was severe in ~40% of the mutants, having few Bhmt+ hepatocytes, 
but mild in the rest of them, having a significant number of the hepatocytes (Figures 23B-23D).  
To determine whether the observed phenotype at R24h later recovered, we examined regenerating 
livers at R48h.  All mutants at R48h still contained a significant number of Tp1:VenusPEST-
/Tp1:H2B-mCherry+ cells negative for Hnf4a (Figure 22C), suggesting that in the absence of 
Tbx2b, BEC-derived cells that failed to differentiate into hepatocytes at R24h do not recover at a 
later time point.  We next examined if BEC dedifferentiation was affected in tbx2b-/- mutants.  
Although Hnf4a expression in regenerating livers at R6h was reduced in the mutants compared 
with their siblings, fabp10a:rasGFP expression appeared to be unaffected in the mutants (Figure 
22D), suggesting that BECs normally dedifferentiate into HB-LCs in the absence of Tbx2b.  
Altogether, data from tbx2b mutant analyses indicate the crucial role of tbx2b in BEC-driven liver 
regeneration, in particular, HB-LC differentiation into hepatocytes. 
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Figure 23: tbx2b mutants exhibit a defect in HB-LC differentiation into hepatocytes 
(A) Experimental scheme illustrating the stage of Mtz treatment and analysis.  (B-D) Single-optical 
section images showing the expression of fabp10a:CFP-NTR, Tp1:VenusPEST, Tp1:H2B-mCherry, 
and Hnf4a (B), Bhmt (C) or Alcam (D) in regenerating livers.  (E) Quantification of the percentage of 
Hnf4a-, Bhmt-, or Alcam+ cells (arrows) among CFP-NTR+/H2B-mCherry+ cells as shown in B-D.  The 
mild cases were used for quantification.  Scale bars: 20 µm; error bars: ±SEM. 
3.2.7 id2a Mutants Temporarily Display an Excess of BECs in Regenerating Livers 
Id2 is a well-known downstream target gene of Bmp signaling in many tissues, including 
pancreatic epithelia [226]; the mouse Id2 promoter contains BMP-responsive elements [277].  
id2a, the zebrafish orthologue of mouse Id2, is also regulated by Bmp signaling in cranial neural 
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crest cells [278].  Not only are Id2 and id2a the direct targets of Bmp signaling, but they also 
mediate the effect of Bmp signaling in these tissues.  Given its BEC-specific expression in the 
developing liver [279] and its regulation by Bmp signaling in regenerating livers (Figure 20A), we 
hypothesized that id2a served as a mediator of Bmp signaling in BEC-driven liver regeneration.  
Using transcription activator-like effector nuclease (TALEN) genome editing technology, we 
generated id2a mutants containing a 22-bp deletion in its first exon.  The mutant larvae did not 
exhibit any liver developmental defects (Figures 24A and 24B) and grew normally to adults.   
 
 
Figure 24: Liver development and BEC number are unaffected in id2a mutants 
(A) Epifluorescence images showing fabp10a:CFP-NTR expression (red) in the uninjured livers of id2a-
/- mutants and wild-type siblings at 5 dpf. (B) Confocal projection images showing the expression of 
fabp10a:CFP-NTR (blue), Alcam (green), and Tp1:H2B-mCherry (red) in the uninjured livers of id2a-/- 
mutants and wild-type siblings at 5 dpf. Scale bars: 300 (A), 20 (B) µm. 
 
BEC-driven liver regeneration appeared to occur normally in id2a-/- mutants, as assessed 
by Hnf4a expression at R6h (Figure 25B) and gc expression at R24h (Figure 25C); however, the 
mutant regenerating livers had significantly more BECs than controls at R30h (Figure 25D), 
 89 
resembling the excessive BEC phenotype seen in regenerating livers treated with DMH1 from 
R0h.  This increased BEC number was due to increased proliferation, as revealed by EdU labeling 
(Figure 25E).  However, this BEC phenotype was temporary because there was no difference in 
BEC number between wild-type and id2a-/- mutant regenerating livers at R72h (Figure 25F).  
Altogether, data from id2a mutant analyses suggest that id2a mediates, in part, the effect of Bmp 
signaling on BEC proliferation during BEC-driven liver regeneration. 
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Figure 25: id2a mutants have excessive BECs in regenerating livers at R30 but recover by R72h 
(A) Experimental scheme illustrating the stages of Mtz treatment and analysis.  (B) Single-optical section 
images showing Hnf4a and Tp1:H2B-mCherry expression in regenerating livers.  (C) WISH images 
showing gc expression in regenerating livers.  (D) Confocal projection images showing the expression 
of Alcam, Tp1:H2B-mCherry, and fabp10a:CFP-NTR in regenerating livers.  Quantification of the total 
numbers of BECs (Alcam+/H2B-mCherry+) per liver.  (E) Confocal projection images showing EdU 
labeling and Alcam and Tp1:H2B-mCherry expression in regenerating livers.  EdU was treated from 
R24h for 6 hours.  Arrows point to EdU+ BECs.  Quantification of the percentage of EdU+ cells among 
BECs. (F) Confocal projection images showing the expression of Alcam (green), Tp1:H2B-mCherry 
(red), and fabp10a:CFP-NTR (blue) in the regenerating livers of id2a-/- mutants and wild-type siblings 
at R72h. Quantification of the total numbers of BECs (Alcam+/H2B-mCherry+) per liver is shown.  Scale 
bars: 50 (B, C, D, E), 20 (F) µm; error bars: ±SEM.  
3.2.8 BMP2 Addition Promotes the Differentiation of a Murine Liver Progenitor Cell 
Line into Hepatocytes in vitro 
To explore whether the findings from the zebrafish liver injury model can be translated to 
mammals, we used a murine liver progenitor cell line that was established from DDC-diet fed mice 
[116]. These cells can efficiently differentiate into either hepatocytes or BECs depending on 
culture conditions [116]. In the hepatocyte differentiation condition, addition of BMP2 
significantly increased the expression of three hepatocyte markers, G6pc, Tat and Tdo2 (Figure 
26), consistent with findings from the zebrafish studies.  
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Figure 26: BMP2 treatment promotes the differentiation of a murine liver progenitor cell line into  
    hepatocytes in vitro 
qPCR data showing the relative expression levels of G6pc, Tat, and Tdo2 between control and BMP2 
treatment (n=4). Error bars: ±SEM. 
3.3 METHODS 
3.3.1 Zebrafish Lines 
Experiments were performed with approval of the Institutional Animal Care and Use Committee 
at the University of Pittsburgh.  We used smad5m169, tbx2bc144, and id2apt661 mutant and the 
following transgenic lines: Tg(fabp10a:rasGFP)s942, Tg(Tp1:VenusPEST)s940, Tg(Tp1:H2B-
mCherry)s939, Tg(ubb:loxP-EGFP-loxP-mCherry)cz1701, Tg(Tp1:CreERT2)s959, Tg(fabp10a:CFP-
NTR)s931, Tg(hs:dnBmpr1)w30, Tg(fabp10a:CreERT2)pt602, Tg(WRE:d2GFP)kyu1, and 
Tg(Tp1:mAGFP-gmnn)s707.  Their full names and references are listed in Table 1 (see Appendix 
A). 
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3.3.2 Hepatocyte Ablation and Chemical Treatment 
Hepatocyte ablation was performed by treating Tg(fabp10a:CFP-NTR) larvae with 10 mM Mtz in 
egg water supplemented with 0.2% DMSO and 0.2 mM 1-phenyl-2-thiourea, as previously 
described [149].  To suppress Bmp signaling and Notch signaling, 10 µM DMH1 (Tocris, Bristol, 
UK) and 5 µM LY411575 (Cayman Chemical, Ann Arbor, MI), respectively, were prepared in 
100% DMSO.  
3.3.3 RNAseq Analysis 
Over 100 livers were manually dissected for each condition (three non-ablating controls at 4.25, 
5.25, and 6 days post-fertilization (dpf) and four regenerating livers at A18h, R6h, R12h, and 
R24h); total RNA was extracted from the dissected livers using the RNeasy Mini Kit (Qiagen, 
Valencia, CA).  This RNA preparation was repeated three times and three-replicate RNA samples 
were mixed.  These mixed samples were processed for single-end deep-transcriptome sequencing 
using the Illumina HiSeq 2000 platform, of which service was provided from Tufts University 
Core Facility.  Galaxy was used to analyze the sequencing reads. 
3.3.4 Generation of Tg(Tp1:mAGFP-gmnn) and id2a Mutant Lines 
The Tp1:mAGFP-gmnn construct was generated by first replacing the EF1 promoter in the 
pT2KXIGΔin vector [280] with the Tp1 module (multiple RBP-Jκ-binding sites in front of a 
minimal promoter) and then placing mAGFP-gmnn [281] downstream of the Tp1 element and a 5’ 
beta-globin intron.  The final construct together with Tol2 mRNA was injected into one-cell stage 
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embryos as previously described [282].  The left (TAL3100, Plasmid #41274) and the right 
(TAL3101, Plasmid #41275) TALEN constructs of id2a were obtained from Addgene.  The id2a 
target sequences are in the first exon, upstream of the helix-loop-helix domain; the spacer region 
contains a TfiI restriction enzyme site.  After linearization with SmaI digestion, the TALEN mRNA 
was synthesized using the Ambion mMESSAGE mMACHINE T7 Ultra Transcription Kit 
(Thermo Fischer Scientific, Waltham, MA).  id2a TALEN mRNAs were mixed at a 1:1 ratio to a 
final concentration of 200 ng/ul and subsequently injected into one-cell-stage embryos.  Either the 
adult zebrafish’ tail fin or whole embryo at 1-2 dpf was used to obtain genomic DNA for PCR-
mediated genotyping.  PCR products were sequenced to identify a frameshift mutation.  F1 fish 
containing a 22-bp deletion was selected to establish the id2a mutant line. 
3.3.5 Generation of tbx2b, smad5 and id2a Mutants 
For id2a genotyping, genomic DNA was amplified with the forward (5’- 
TCCTGCTGTCAACATGAAGGCA -3’) and reverse (5’-AGTCGAGCGCGATCTGCAGG-3’) 
primers, followed by digestion with TfiI.  The wild-type allele generates two bands of 179 and 87 
bp, whereas the id2a mutant allele generates a band of 244 bp.  tbx2b [276] and smad5 [273] 
genotyping were performed as previously described. 
3.3.6 Heat-shock Condition 
Tg(hs:dnBmpr1) larvae were heat-shocked at A30h or R8h by transferring them into egg water 
pre-warmed to 39°C and kept at this temperature for 20 minutes as previously described [70]. 
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3.3.7 Cre/loxP-mediated Lineage Tracing 
Fish carrying the Tp1:CreERT2 or fabp10a:CreERT2 transgene were crossed to the reporter line, 
Tg(ubb:loxP-GFP-loxP-mCherry).  Larvae from the crosses were treated with Mtz from 3.5 to 5 
dpf and additionally treated with both 5 μM 4-OHT and 10 μM DMH1 (Tocris, Bristol, UK) from 
A33h to R6h for 9 hours.  At R54h, 48 hours after 4-OHT and DMH1 washout, the larvae were 
harvested and processed for immunostaining to reveal lineage-traced mCherry+ cells as previously 
described [20]. 
3.3.8 EdU Labeling 
EdU labeling was performed according to the protocol outlined in the Click-iT EdU Alexa Fluor 
647 Imaging Kit (Life Technologies, Grand Island, NY).  Larvae were treated with egg water 
containing 10 mM EdU and 5% DMSO.  After a 6-hour EdU treatment, the larvae were harvested 
for subsequent analysis. 
3.3.9 Whole-mount In Situ Hybridization (WISH) and Immunostaining 
WISH was performed as previously described [242].  cDNA from livers at 5 dpf or R6h was used 
as a template for PCR to amplify genes-of-interest; PCR products were used to make in situ probes.  
The primers used for the probe synthesis are listed in Table 2 (see Appendix A).  Whole-mount 
immunostaining was performed as previously described [149], using the following antibodies: 
rabbit anti-Prox1 (GTX128354, GeneTex, Irvine, CA), goat anti-Hnf4a (Santa Cruz, Dallas, TX), 
chicken anti-GFP (Aves Labs, Tigard, OR), mouse anti-Bhmt (1:500; a gift from J. Peng, Zhejiang 
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University, China), mouse anti-Alcam (ZIRC, Eugene, OR), rat anti-mCherry (Allele 
Biotechnology, San Diego, CA), and Alexa Fluor 488-, 568-, and 647-conjugated secondary 
antibodies (Life Technologies, Grand Island, NY). 
3.3.10 Quantitative RT-PCR (qPCR) 
Total RNA was extracted from 100 dissected livers using the RNeasy Mini Kit (Qiagen, Valencia, 
CA); cDNA was synthesized from the RNA using the SuperScript® III First-Strand Synthesis 
SuperMix (Life Technologies, Grand Island, NY) according to the kit protocols.  qPCR was 
performed as previously described [283], using the Bio-Rad iQ5 qPCR machine with the iQTM 
SYBR Green Supermix (Bio-Rad, Hercules, CA).  eef1b2 was used for normalization.  At least 
three independent experiments were performed.  The primers used for qPCR are listed in Table 3. 
3.3.11 Mouse LPC Cell Line and Culture Condition 
The LPC cell line, HSCE1, used in this study was established and maintained as described 
previously [284].  For their differentiation into hepatocytes, HSCE1 cells were cultured in the 
presence of 1% DMSO and 20 ng/mL mouse Oncostatin M with or without 500 ng/mL 
recombinant human BMP2 (Peprotech, Rocky Hill, NJ) (n = 4).  After 5 days of hepatocyte 
induction, the cultured cells were harvested for RNA preparation.  HSCE1 cells before the 
induction were used as a negative control. TRIzol reagent (Invitrogen, Carlsbad, CA) was used to 
extract total RNA; PrimeScript RT reagent kit (Takara, Shiga, Japan) was used to synthesize 
cDNA, according to the kit protocols.  qPCR was conducted with a LightCycler 480 system and 
Universal Probe Library (Roche Diagnostics, Indianapolis, IN).  The Universal Probe Library 
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Mouse Actb Gene Assay was used for normalization.  The primers used for qPCR are listed in 
Table 3. 
3.3.12 Image Acquisition, Processing and Statistical Analysis 
Zeiss LSM700 confocal and Leica M205 FA epifluorescence microscopes were used to obtain 
image data.  Confocal stacks were analyzed using the Zen 2009 software.  All Figures, labels, 
arrows, scale bars, and outlines were assembled or drawn using the Adobe Illustrator software.  
Unpaired two-tailed Student’s t-test was used for statistical analysis; P<0.05 was considered 
statistically significant.  Quantitative data were shown as means ±SEM. 
3.4 DISCUSSION 
Using the zebrafish hepatocyte ablation model, we elucidate two distinct roles of Bmp signaling 
in BEC-driven liver regeneration: (1) initially, Bmp signaling regulates HB-LC differentiation 
into hepatocytes; (2) later, Bmp signaling controls the proliferation of newly-generated BECs.  
By analyzing the mutants of smad5, tbx2b, and id2a, genes involved in the Bmp signaling 
pathway, we discovered that Smad5 is the main receptor-regulated Smad during BEC-driven 
liver regeneration and that Tbx2b and Id2a mediate its effect on HB-LC differentiation into 
hepatocytes and on BEC proliferation, respectively. In addition, no difference in cell apoptosis 
was observed between DMSO- or DMH1-treated regenerating livers (Figure 27).  
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Figure 27: Inhibition of Bmp signaling does not affect cell death in regenerating livers at R6h 
Single-optical section images showing Tp1:H2B-mCherry (red), Tp1:VenusPEST (green) expression 
and TUNEL+ cells (gray) in DMSO- and DMH1-treated regenerating livers at R6h. Arrows point to cells 
positive for both TUNEL and H2B-mCherry. Scale bar: 20 µm. 
 
Bmp [70, 76], Fgf [69, 70], and Wnt/β-catenin signaling [28] are implicated in 
hepatoblast specification and proliferation during liver development.  Given that regeneration 
often recapitulates development and key developmental factors are re-utilized during 
regeneration, these signaling pathways may also regulate liver regeneration.  During hepatocyte-
driven liver regeneration, both Wnt/β-catenin [285] and Fgf signaling [286] promote hepatocyte 
proliferation.  During BEC-driven liver regeneration, Wnt/β-catenin signaling promotes oval cell 
proliferation [287] and Fgf signaling induces oval cell activation [139].  In contrast to Wnt/β-
catenin and Fgf signaling, the influence of Bmp signaling on hepatocyte proliferation during 
hepatocyte-driven liver regeneration is ligand-dependent: BMP4 signaling through Alk3 
represses hepatocyte proliferation, whereas BMP7 signaling through Alk2 promotes hepatocyte 
proliferation [169].  Previous in vitro studies have reported on the role of BMP signaling in the 
differentiation of LPCs into hepatocytes: BMP4 treatment induced the differentiation of rat 
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hepatic progenitor cells [288] and CD133+ hepatic cancer stem cells [289] into hepatocytes.  Our 
in vitro and in vivo data support these findings and further reveal the crucial role of Bmp 
signaling in BEC-driven liver regeneration, specifically during the differentiation phase of LPCs 
into hepatocytes. 
To further elucidate the mechanisms by which Bmp signaling controls BEC-driven liver 
regeneration, we analyzed tbx2b and id2a mutants.  Our RNAseq data revealed that at R6h, both 
tbx2b (among the T-box transcription factor genes) and id2a (among the Id family genes) were 
highly upregulated in regenerating livers compared with the other tbx and id genes (Figure 28A 
and 28B), suggesting their importance in BEC-driven liver regeneration.  As expected, both 
tbx2b and id2a expression decreased in both DMH1-treated and smad5-/- regenerating livers.  
Importantly, tbx2b-/- mutants exhibited a defect in HB-LC differentiation into hepatocytes and 
id2a mutants exhibited excessive BECs in regenerating livers at R30h, revealing tbx2b and id2a 
as the key downstream mediators of Bmp signaling that regulates BEC-driven liver regeneration.   
 
Figure 28: Expression levels of tbx and id genes in regenerating livers at R6h 
(A, B) Graphs showing the expression levels of 16 tbx (A) and 5 id (B) genes in control and regenerating 
livers at R6h.  FPKM stands for fragments per kilobase of exon per million fragments mapped.   
 
Using a morpholino-mediated knockdown approach, we previously reported that during 
liver development, Id2a positively regulates hepatic outgrowth through hepatoblast proliferation 
and survival [279].  However, we found that during BEC-driven liver regeneration, Id2a 
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negatively regulates the proliferation of newly-generated BECs.  Although we did not detect any 
developmental defects in the id2a-/- mutants, inconsistent with the morpholino results, this 
discrepancy might be explained by the genetic compensations that can occur in mutants but not 
in morphants [290].  Previous rodent studies have highlighted the role of Id1 and Id2 in 
hepatocyte-driven liver regeneration.  Following partial hepatectomy, not only Id1 was 
upregulated in liver sinusoidal endothelial cells (LSECs), but Id1-/- mice displayed abnormal 
liver function and impaired liver regeneration [291].  In fact, following acute liver injury, Id1 
was induced downstream of LSEC-specific upregulation of CXCR4/CXCR7 [292].  As a result, 
ID1 promotes the secretion of pro-regenerative angiocrine factors, such as Wnt2 and HGF, to aid 
in hepatocyte proliferation after liver injury [291, 292].  Similar to Id1, Id2 levels also increased 
after partial hepatectomy and bile duct ligation in rats [259], but its role in liver regeneration has 
not yet been reported.  
While Wnt/β-catenin signaling promotes LPC differentiation into hepatocytes, Notch 
signaling represses the process [141, 293].  Here, we presented Bmp signaling as another 
regulator of this differentiation process.  Since we did not observe any changes in Wnt activity 
between DMSO- and DMH1-treated regenerating livers (Figure 29), it appears that Bmp 
signaling does not affect Wnt/β-catenin signaling.   
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Figure 29: Inhibition of Bmp signaling does not affect Wnt activity in regenerating livers at R6h 
Single-optical section images showing WRE:d2GFP (green) and Tp1:H2B-mCherry (red) expression in 
regenerating livers at R6h.  The Wnt reporter line, Tg(WRE:d2GFP), was used to reveal hepatic Wnt 
activity.  Scale bar: 20 µm. 
 
However, sustained, weak Notch activity observed in DMH1-treated regenerating livers 
suggests that Bmp signaling may suppress Notch signaling.  Although it was reported that 
repression of Notch signaling promotes LPC differentiation into hepatocytes [141, 293], the 
hepatocyte differentiation defects observed in DMH1-treated livers were not rescued by 
inhibiting Notch signaling globally (Figure 30).  Thus, it is unlikely that Bmp signaling controls 
LPC differentiation through Wnt/β-catenin or Notch signaling.  However, we do not exclude the 
possibility that Wnt/β-catenin and Notch signaling control LPC differentiation through Bmp 
signaling. 
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Figure 30: Hepatocyte differentiation defect observed in DMH1-treated larvae is not rescued by the  
    global inhibition of Notch signaling 
Confocal projection images showing the expression of fabp10a:CFP-NTR (blue), Tp1:H2B-mCherry 
(red), Tp1:VenusPEST (green) and Bhmt (gray) in regenerating livers treated with DMSO, DMH1, 
LY411575 (Notch inhibitor) and DMH1+LY411575 at R24h. Scale bar: 20 µm.   
 
The zebrafish hepatocyte ablation model has contributed significantly to a better 
understanding of BEC- or LPC-driven liver regeneration.  We previously reported that Wnt/β-
catenin signaling via Wnt2bb regulates the proliferation of newly-generated hepatocytes [20] and 
that BET proteins regulate BEC dedifferentiation and the proliferation and maturation of newly-
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generated hepatocytes [266].  Using the same model, others also reported on the involvement of 
Notch signaling in BEC-driven liver regeneration [294].  Here, we provide the gene expression 
profiles of regenerating livers at four distinct stages, A18h, R6h, R12h, and R24h.  Although we 
focus on Bmp signaling and its downstream target genes in this study, these expression profiles 
will be useful for identifying other crucial genes involved in regulating BEC-driven liver 
regeneration. 
In summary, we discovered that Bmp signaling regulates HB-LC differentiation into 
hepatocytes, partly, via Tbx2b and controls the proliferation of newly-generated BECs via Id2a.  
Liver biopsies of human patients suffering from chronic liver diseases display an abundance of 
oval cells, also known as HB-LCs.  To promote the differentiation of these oval cells into 
hepatocytes in these patients, one possible therapy may involve enhancing hepatic Bmp signaling. 
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4.0  STAT3 SIGNALING REGUALTES BILIARY-DRIVEN LIVER 
REGENERAITON IN ZEBRAFISH 
4.1 BACKGROUND 
With the story of an eagle picking at Prometheus’ liver daily, the Ancient Greeks first eluded to 
the remarkable ability of the liver to regenerate. To date, no true stem cell population has been 
identified in the liver. Instead, extensive studies have revealed two main methods of liver 
regeneration depending on the severity of the liver injury: (1) hepatocyte-driven or (2) biliary 
epithelial cell (BEC)-driven. Typically following liver injury, hepatocytes proliferate to restore the 
lost liver mass [112, 295]. However, if hepatocyte proliferation is blocked, then the BECs undergo 
dedifferentiation into hepatoblast-like cells (HB-LCs), also termed liver progenitor cells (LPCs) 
[261]. LPCs are bipotent [116], facultative resident stem progenitor cells that express both 
hepatocyte and BEC markers and can differentiate into mature hepatocytes and BECs to restore 
the lost liver mass [116, 117, 131].   
Moreover, LPCs observed in our zebrafish model of liver regeneration share similar 
characteristics with the BEC-derived oval cells or ductular reactions observed in both rodents and 
human severe acute or chronic liver injury conditions [132, 144, 149]. Currently, chronic liver 
disease and cirrhosis are the 12th leading cause of death in the United States [296]. Although liver 
transplantation offers an effective therapy, more than 50% of patients on the transplant waiting list 
never receive a donor liver transplant [2]. Due to this shortage, an essential step in treating liver 
disease and augmenting the innate regenerative process is understanding the underlying mediators 
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and mechanisms of LPC-driven liver regeneration, including LPC activation, proliferation and 
differentiation. 
With that goal in mind, our lab and others have previously reported on a zebrafish model 
in which following complete hepatocyte ablation, BECs extensively contribute to hepatocyte 
regeneration [132, 149]. This phenomenon is not zebrafish exclusive, however, as the BEC-to-
hepatocyte-mediated regeneration was similarly observed in a hepatocyte-specific Mdm2-/- mouse 
model of liver injury [131].  
One of the hallmarks of a LPC activation is the infiltration of inflammatory cells, including 
macrophages and leukocytes, into the injured liver [136]. These inflammatory cells then secrete 
specific cytokines, which can contribute to LPC/oval cell activation and proliferation [297-300]. 
One mouse model of oval cell activation is the choline-deficient, ethionine-supplemented (CDE) 
diet; mice on a CDE diet display an increased release of cytokines, such as IL-6, after liver injury. 
Once IL-6 binds to its cognate receptor and co-receptor, gp130-associated Janus tyrosine kinases 
(JAKs) are autophosphorylated and subsequently activated. JAKs can then phosphorylate 
transcription factors, such as signal transducer and activator (STAT) 3, which dimerize and 
translocate to the nucleus to affect downstream target genes [301, 302].  
Previous reports have highlighted the involvement of Stat3 in hepatocyte-driven and oval 
cell-mediated liver regeneration [303, 304]. In the partial hepatectomy model of liver injury, Stat3 
deficiency led to an increased mortality rate and decreased DNA synthesis. In the CDE-diet model 
of liver injury, Stat3 was found to be upregulated in the oval cell population with high proliferative 
potential. In addition, mice with a hepatocyte-specific knock out of Suppressor of cytokine 
signaling 3 (Socs3), a negative regulator of STAT3, display STAT3 hyperactivation after PH, 
which results in enhanced proliferation during regeneration [208]. Given the involvement of Stat3 
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in hepatocyte survival and proliferation after liver injury, we hypothesized that Stat3 signaling 
may also influence zebrafish LPC-driven liver regeneration.   
Here, using the zebrafish hepatocyte ablation liver injury model, we report on the role of 
Stat3 in LPC proliferation and differentiation into hepatocytes. We investigated the role of Stat3 
in LPC-driven liver regeneration by two methods: (1) utilizing a JAK-specific inhibitor to block 
Stat3 activation downstream and (2) utilizing zebrafish Stat3 mutants generated by TALEN 
mutagenesis. Our findings show that Stat3 plays a role in LPC differentiation into hepatocytes by 
regulating LPC proliferation.  
4.2 RESULTS 
4.2.1 Stat3 Inhibition Results in A Decreased Liver Size during Liver Regeneration 
We, and others, have previously characterized a zebrafish BEC-driven liver regeneration model 
where upon extensive hepatocyte ablation, BECs contribute to the repopulation of the liver [132, 
149]. We utilized the Tg(fap10a:CFP-NTR) transgenic fish, which express the bacterial 
nitroreductase (NTR) enzyme fused with the cyan fluorescent protein (CFP) from the hepatocyte-
specific, fabp10a, promoter [149]. Upon treatment of a nontoxic prodrug, metronidazole (Mtz), 
cells expressing NTR metabolize Mtz into a cytotoxic agent [147]. As a result, only hepatocytes 
expressing NTR will undergo near-complete, genetic-based ablation, causing BECs to actively 
contribute to the liver regeneration process through a well-defined mechanism. Initially, the BECs 
dedifferentiate into hepatoblast-like cells (HB-LCs), also termed liver progenitor cells (LPCs). 
Next, these LPCs differentiate into hepatocytes and BECs, concluding with the proliferation of the 
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newly-generated hepatocytes and BECs and the restoration of the liver mass. Using this model, we 
explored the implications of inflammatory signaling, specifically focusing on Stat3, in BEC-driven 
liver regeneration.  
To induce hepatocyte ablation, fabp10a:CFP+ larvae were treated with Mtz from 3.5-5 days 
post fertilization (dpf). Following this 36-hour period (ablation; A36h), Mtz washout was 
considered as the initiation of regeneration (R0h). Based on our RNAseq analysis (unpublished 
data), we found stat3 and its negative feedback regulator, socs3a, were upregulated in regenerating 
livers at R6h compared to non-ablated controls (Figure 31; also see Appendix B). To elucidate the 
role of Stat3 in BEC-driven liver regeneration, we utilized a JAK-specific kinase inhibitor, JSI-
124, that blocks Stat3 activation. JSI-124 has previously been used in zebrafish to block Stat3 
signaling [305, 306]. We assessed the effect of Stat3 inhibition on (1) liver size and morphology; 
(2) BEC dedifferentiation into LPCs; and (3) LPC proliferation and LPC-to-hepatocyte/BEC 
differentiation during BEC-driven liver regeneration.  
 
Figure 31: Expression of stat3 is upregulated in regenerating livers during BEC-driven liver  
            regeneration 
WISH images showing stat3 expression in control, non-ablated livers and Mtz-treated regenerating livers 
at R6h. At R6h, most of liver is composed of BEC-derived progenitor cells, termed LPCs. Numbers 
indicate the proportion of larvae exhibiting the representative expression shown. Arrows point to the 
liver. Scale bar: 100 µm.  
To visualize the liver size in our regeneration setting, we utilized the Tg(fabp10a:DsRed) 
transgenic zebrafish larvae; these larvae express DsRed specifically in the hepatocytes. During the 
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Mtz treatment, Stat3 was inhibited from either A0h (at the start of Mtz treatment), A18h (to block 
Stat3 at time point when macrophages infiltrate into the injured liver and prior to BEC 
dedifferentiation) or R0h (to block Satat3 at later phases of liver regeneration, such as LPC 
proliferation and/or differentiation). Following Mtz washout, the liver size was examined at R24h 
and R48h. JSI-124 treatment significantly reduced the liver size at R24h from both the A0h and 
A18h treatment (Figure 32A-C). However, at R48h, only the A0h treatment resulted in a 
significant reduction of the liver size (Figure 32D-E).  
Furthermore, we validated the effect of blocking Stat3 from A18h-R24h and A18h-R48h 
by using a different inhibitor, S3I-201, which blocks Stat3 dimerization and subsequent 
downstream translocation into the nucleus. Similar to the JSI-124 liver phenotype, S3I-201-treated 
larvae also exhibited a significantly smaller liver size at R24h during BEC-driven liver 
regeneration. Unlike JSI-124, however, continuous treatment of S3I-201 from A18h-R48h still 
caused a significant reduction of the liver size at R48h (Figure 32F-G). Altogether, these data 
suggest Stat3 signaling plays an important role in BEC-driven liver regeneration.  
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Figure 32: Stat3 inhibition decreases size of regenerating livers during BEC-driven liver  
    regeneration 
(A) Scheme illustrating the Mtz treatment period (A, ablation), JSI-124 treatment and liver regeneration 
(R, regeneration). Arrows indicate analysis stages at R24h. (B) Epifluorescence images showing 
fabp10a:DsRed in the regenerating livers treated with DMSO or JSI-124 at the indicated time points. (C) 
Quantification of fabp10a:DsRed expression and area of the regenerating livers treated with JSI-124 at 
three different time points, from A0h-R24h, A18h-R24h and R0h-R24h. Total cell fluorescence (AU: 
arbitrary units) considers both area of the liver and fluorescence intensity. (D) Scheme illustrating the Mtz 
treatment period (A, ablation), JSI-124 treatment and liver regeneration (R, regeneration). Arrows indicate 
analysis stage at R48h. (E) Quantification of fabp10a:DsRed expression and area of the regenerating livers 
treated with JSI-124 at three different time points, from A0h-R48h, A18h-R48h and R0h-R48h. Total cell 
fluorescence (AU: arbitrary units) considers both area of the liver and fluorescence intensity. Scale bar: 
250 µm; error bars: ±SEM. 
 
Next, we sought to determine which step of BEC-driven liver regeneration was regulated 
by Stat3. To address this question we examined (1) BEC dedifferentiation and (2) LPC 
proliferation and/or differentiation into hepatocytes/BECs. First, to inspect BEC dedifferentiation 
into LPCs, we examined the induction of hepatoblast/hepatocyte marker, hepatocyte nuclear factor 
4 alpha (Hnf4a), in Tp1:H2B-mCherry+ cells (BECs), indicative of dedifferentiated BECs. We 
used the Tg(Tp1: H2B-mCherry) transgenic line in which the H2B-mCherry fusion protein is 
driven by the Notch response element to mark BECs/BEC-derived cells [271]. Interestingly, in 
A0h-R6h JSI-124-treated larvae, the induction of Hnf4a in Tp1:H2B-mCherry+ cells was 
comparable to DMSO-treated control livers (Figure 33).  Altogether, these data reveal Stat3 
inhibition decreases the size of regenerating livers during BEC-driven liver regeneration. 
However, this phenotype is not due to a defect in BEC dedifferentiation. Next, we examined 
whether the smaller liver size was due to a LPC proliferation or a hepatocyte differentiation defect.  
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Figure 33: Stat3 inhibition does not affect the BEC dedifferentiation into LPCs during BEC-driven  
    liver regeneration 
Scheme illustrating the Mtz treatment period (A, ablation), JSI-124 treatment and liver regeneration (R, 
regeneration). Arrow indicates analysis stage at R6h. Single-optical section image showing 
Tp1:VenusPEST (green), Tp1:H2B-mCherry (red) expression and Hnf4a staining (gray) in regenerating 
livers at R6h. Scale bar: 20 µm.  
4.2.2 Stat3 Inhibition Temporarily Delays LPC-to-hepatocyte Differentiation and 
Decreases BEC number during Liver Regeneration 
Since BEC dedifferentiation into LPCs was unaffected in Stat3-inhibited regenerating livers, we 
next examined the effect of blocking Stat3 on LPC-to-hepatocyte differentiation at later stages of 
regeneration. We used the Betaine-homocysteine S-methyltransferase (Bhmt) to mark newly-
generated hepatocytes. At R6h, upon Stat3 inhibition, Bhmt expression was visibly reduced in 
75% of the regenerating livers, indicative of a LPC-to-hepatocyte differentiation defect (Figure 
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34). Interestingly, this LPC-to-hepatocyte differentiation defect was temporary, as at a later stage, 
such as R24h, Bhmt expression in both DMSO- or JSI-124-treated livers was comparable (Figure 
34). In addition, when BECs dedifferentiate, Alcam, a marker of BECs in zebrafish [270], is 
expressed in BEC-derived LPCs. Later, when LPCs differentiate into hepatocytes, Alcam 
expression disappeared from mature hepatocytes. JSI-124 treatment from A0h resulted in 
sustained Alcam expression at R24h in mCherry-positive cells, providing further evidence for a 
hepatocyte differentiation defect (Figure 35A). In addition to the delayed hepatocyte 
differentiation in Stat3-inhibited regenerating livers, JSI-124 treatment significantly decreased the 
BEC number at R24h (Figure 35A). Unlike the hepatocyte differentiation defect, which was 
temporary, the BEC number remained low even at later time points (Figure 36A). Importantly, 
JSI-124 treatment in non-ablated control livers had no effect on liver morphology or on BEC 
number (Figure 35B). 
 
 
Figure 34: Stat3 inhibition delays LPC-to-hepatocyte differentiation during BEC-driven liver  
    regeneration 
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Scheme illustrating the Mtz treatment period (A, ablation), JSI-124 treatment and liver regeneration (R, 
regeneration). Arrows indicate analysis stage at R6h and R24h. Confocal projection images showing 
Tp1:H2B-mCherry expression and Bhmt staining (gray) in regenerating livers treated with DMSO and 
JSI-124 at R6h and R24h. Scale bars: 20 µm.  
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Figure 35: Stat3 inhibition decreases BEC number during BEC-driven liver regeneration and has no  
    effect on non-ablated livers 
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(A) Confocal projection images showing Tp1:H2B-mCherry (red) expression and Alcam (gray) staining 
in regenerating livers at R24h.  Quantification of the total numbers of BECs (Alcam+/H2B-mCherry+) 
per liver.  (B) Confocal projection images showing Tp1:H2B-mCherry (red), Tp1:VenusPEST (green), 
fabp10a:CFP-NTR (blue) expression and Alcam (gray) staining in regenerating livers treated with 
DMSO and JSI-124 at 6 dpf. Quantification of the total numbers of BECs (Alcam+/H2B-mCherry+) per 
liver. Scale bars: 20 µm; error bars: ±SEM. 
 
We further examined the impact of delayed LPC-to-hepatocyte differentiation and reduced 
BEC number by investigating hepatocyte polarity and biliary morphogenesis. Typically expressed 
on the apical side of the hepatocyte membrane, the bile salt export pump marker, ATP binding 
cassette subfamily B member 11 (Abcb11) marks the bile canaliculi in hepatocytes [66, 307]. The 
number of Abcb11+ cells per liver area was significantly decreased in JSI-124-treated livers as 
compared to DMSO-treated controls (Figure 36A). We confirmed the Abcb11-phenotype with the 
BODIPY C5 Analog Assay, which allowed us to visualize the intrahepatic biliary conduits and 
processing of C5 lipid analog as it passed through the biliary network [308]. Compared to the 
DMSO-treated control livers, which had thin and elongated bile canaliculi, JSI-124-treated livers 
had a reduced number of biliary conduits as well as short or absent bile canaliculi (Figure 36B).  
Altogether, these data implicate Stat3 as an important regulator in the timing for LPC-to-
hepatocyte differentiation and in the establishment of proper BEC population during BEC-driven 
liver regeneration.  
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Figure 36: Stat3-inhibited livers maintain low BEC numbers and display aberrant intrahepatic  
    biliary morphogenesis 
(A) Confocal projection images showing Tp1:H2B-mCherry (red) expression and Abcb11 (green) 
staining in regenerating livers at R54h. Quantification of the total number of BECs (H2B-mCherry+ 
cells) and bile canaliculi (Abcb11+ cells) per liver area. (B) Confocal projection images showing 
BODIPY C5 staining (green) and Tp1:H2B-mCherry (red) expression at R54h. Inset boxes show a 
magnified image of the selected area. Arrows point to bile ductules. Right: Scheme of bile ductules and 
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bile canaliculi in DMSO- and JSI-124-treated regenerating livers at R54h. Scale bars: 20 µm; error bars: 
±SEM. 
4.2.3 Stat3 inhibition Reduces the Regenerating Liver Size and BEC number due to a 
Proliferation Defect 
Given the smaller liver size and reduced number of BECs observed in JSI-124-treated livers, we 
investigated whether the observed phenotypes were due to cell death or a proliferation defect. To 
assess cell proliferation, we used the 5-ethynyl-2’-deoxyuridine (EdU) labeling and the cell cycle 
reporter line, Tg(fabp10a:mAGFP-gmnn) [143]. Based on the cell cycle oscillator phenomenon 
with Cdt1 and Geminin proteins, this transgenic line only labels hepatocytes in the S/G2/M phases 
of the cell cycle [309]. Since we observed a gross phenotype (i.e., smaller liver size) at R24h, we 
hypothesized that any proliferation or cell death defect would occur prior to R24h. At R24h, we 
expected no change in EdU labeling of hepatocytes since at R48h, we observed no significant 
difference in the size of regenerating livers (Figure 32E). Following this logic, we conducted our 
EdU and transgenic cell cycle assays at R6h and R24h. Since the fabp10a:mAGFP-gmnn labels 
proliferating LPCs at R6h, we found that compared to the DMSO-control livers, JSI-124-treated 
regenerating livers displayed a significant decrease in LPC proliferation at R6h (Figures 37A-B). 
As expected, however, this proliferation defect was temporary as at R24h, the JSI-124-treated 
livers recovered and proliferation was unaffected (data not shown).  
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Figure 37: Stat3 inhibition reduces the regenerating liver size and BEC number due to a  
    proliferation defect 
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(A) Confocal projection images showing Tp1:H2B-mCherry (red) and fabp10a:mAGFP-gmnn (gray) 
expression in regenerating livers at R6h. Quantification of the percent fucci+ cells per total number of 
BECs (H2B-mCherry+ cells) in the liver. (B) Confocal projection images showing Tp1:H2B-mCherry 
(red) expression and EdU staining (green) in regenerating livers at R6h. Quantification of the percent 
EdU+ cells per total number of BECs (H2B-mCherry+ cells) in the liver. Scale bars: 20 µm; error bars: 
±SEM. 
 
To assess cell death, we used the Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay to label dying cells in the DMSO- and JSI-124-treated regenerating livers 
at A18h and R6h. At A18h, extensive hepatocyte death and macrophage infiltration is typically 
observed in BEC-driven liver regeneration. Again, the gross decrease of liver size at R24h points 
to the after-effect of an earlier defect in either proliferation and/or cell death. Since we observed a 
proliferation defect at R6h, we also anticipated any difference in cell death to occur at R6h. 
However, at both A18h and R6h, we observed no significant difference in TUNEL/Tp1:H2B-
mCherry-double positive cells between DMSO- or JSI-124-treated regenerating livers (Figures 
38A-B).  
Altogether, these data provide evidence that the smaller liver size and decreased BEC 
number is not due to an increase in cell death, but rather a proliferation defect. In addition to its 
role in the timing of LPC-to-hepatocyte differentiation and BEC number maintenance, Stat3 
signaling also appears to mediate LPC proliferation.  
 121 
 
Figure 38: Stat3 inhibition has no effect on cell death in regenerating livers  
(A) Confocal projection images showing Tp1:H2B-mCherry (red) expression and TUNEL+ (green) at 
A18h. Quantification of the total number of TUNEL+ cells per liver area at A18h. (B) Confocal 
projection images showing Tp1:H2B-mCherry (red) expression and TUNEL+ (green) at R6h. 
Quantification of the total number of TUNEL+ cells per liver area at R6h. Scale bars: 20 µm; error bars: 
±SEM. 
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4.3 METHODS 
4.3.1 Zebrafish Maintenance 
Embryos and adult zebrafish (Danio rerio) were raised and maintained under standard laboratory 
conditions [239] with protocols approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. We used stat3sa15744 mutants [310] and the following transgenic lines: 
Tg(fabp10a:DsRed,ela31:GFP)gz12 [39] [referred to as Tg(fabp10a:dsRed)], Tg(EPV.Tp1-
Mmu.Hbb:Venus-Mmu.Odc1)s940 [311] [referred to as Tg(Tp1:VenusPEST)], Tg(EPV.Tp1-
Mmu.Hbb:hist2h21-mCherry)s939 [311] [referred to as Tg(Tp1:H2B-mCherry)], Tg(fabp10a:CFP-
NTR)s931 [20] [referred to as Tg(fabp10a:CFP-NTR)], and Tg(fabp10a:mAGFP-gmnn)pt608 [143] 
[referred to as Tg(fabp10a:mAGFP-gmnn)].  
4.3.2 Hepatocyte Ablation and Chemical Inhibitor Treatments 
To ablate hepatocytes, Tg(fabp10a:CFP-NTR) or Tg(fabp10a:CFP-NTR; fabp10a:dsRed) double 
transgenic larvae were treated with 10 mM metronidazole (Mtz) in egg water supplemented with 
0.2% dimethyl sulfoxide (DMSO) and 0.2 mM 1-phenyl-2-thiourea (PTU) as previously described 
[149]. For Stat3 inhibitor experiments, larvae were treated with 7 uM JSI-124 (also known as 
Cucurbitacin I, Cayman Chemical, Ann Arbor, MI, USA) or 300 uM S3I-201 (Sigma-Aldrich, St. 
Louis, MO, USA). Larvae were treated with JSI-124 or S3I-201 from A0h to R24h or from A18h 
to R24h followed by the examination of fabp10a:DsRed expression and liver size at R24h or R48h 
using the Leica M205 FA microscope. 
 123 
4.3.3 Zebrafish Whole-mount In Situ Hybridization (WISH) and Immunostaining 
Whole-mount in situ was performed as previously described [242]. Whole-mount immunostaining 
was performed as previously described [29], using the following antibodies: goat anti-Hnf4a (1:35; 
Santa Cruz, Dallas, TX), mouse monoclonal anti-Bhmt (1:100; a gift from J. Peng, Zhejiang 
University, China), mouse monoclonal anti-Alcam (1:10; ZIRC, Eugene, OR) and rabbit 
polyclonal anti-Abcb11 (1:100; PC-064, Kamiya Biomedical, Seattle, WA), and Alexa Fluor 488-
, 568-, and 647-conjugated secondary antibodies (1:300; Life Technologies, Grand Island, NY). 
4.3.4 TUNEL and EdU Assays 
Apoptotic cell death was analyzed according to the protocol of the In Situ Cell Death Detection 
Kit, TMR Red (Roche, Switzerland). Following whole-mount immunostaining, TUNEL labeling 
was applied. Cell Proliferation was performed using the protocol outlined in the Click-iT EdU 
Alexa Fluor 647 Imaging Kit (Life Technologies, Grand Island, NY, USA). Larvae were treated 
with egg water supplemented with 0.2 mM PTU containing 50 mM EdU and 5% DMSO at R0h 
or R18h. After a 6-hour treatment window, larvae were harvested at either R6h or R24h, 
respectively, and fixed in fresh 3% formaldehyde overnight at 4°C. After fixation, samples were 
prepared for subsequent imaging and statistical analysis. 
4.3.5 Image Acquisition, Processing and Statistical Analysis 
Zeiss LSM700 and Leica M205 FA were used for confocal microscopy and epifluorescence 
microscopy, respectively. ZEN 2009 software was used to assemble and analyze confocal stacks. 
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Leica MZ16 stereomicroscope was used to obtain in situ images. Adobe Illustrator, Photoshop and 
Microsoft Powerpoint were used for assembling figures, tables, schematics and labels. GraphPad 
Prism 7 software was used to create and assemble quantitative data. Quantification for liver size, 
fluorescence, and cell counting was performed using the NIH ImageJ software. Unpaired two-
tailed Student's t-tests were used for statistical analyses; p < 0.05 was considered statistically 
significant. Quantitative data are shown as means  standard error of the mean (SEM). 
4.3.6 BODIPY C5 Lipid Analog Assay 
A 2-hour treatment of 0.5 uM BODIPY C5 (Life Technologies, Grand Island, NY) [308] was used 
to assess ductal morphology and morphogenesis in DMSO- vs. JSI-124-treated regenerating livers. 
Following BODIPY treatment, larvae were rinsed briefly and anesthetized with 0.016% Tricaine 
in egg water supplemented with 0.2 mM PTU and mounted in 1% low-melting agarose for confocal 
imaging. 
4.4 DISCUSSION 
The signaling pathways regulating LPC proliferation and differentiation into hepatocytes and 
BECs during BEC-driven liver regeneration remain poorly understood. In this study, we sought to 
determine the role of Stat3 in BEC-driven liver regeneration. We blocked Stat3 signaling with the 
JAK-inhibitor, JSI-124, which reduced the size of regenerating livers at R24h. To further elucidate 
the exact process of liver regeneration being affected by JSI-124, we examined (1) BEC 
dedifferentiation and (2) LPC proliferation and differentiation into hepatocytes/BECs. First, by 
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Hnf4a staining, we found BEC dedifferentiation was unaffected in JSI-124-treated livers, as 
compared to DMSO-controls. We further noted that Stat3 deficiency decreased the number of 
mature BECs in regenerating livers at R24h and this decrease was still maintained later at R54h. 
Lastly, our data revealed that Stat3 inhibited-livers exhibited a decrease in LPC proliferation at 
R6h (but not at R24h) during liver regeneration, which helps to explain the decreased liver size at 
R24h and subsequent recovery later on at R48h.  
Using our zebrafish BEC-driven liver regeneration model, our RNAseq analysis 
(unpublished) and WISH analysis highlighted the upregulation of stat3 in the initial phases of liver 
regeneration (Figure 31). It was also reported that in the 2-AAF/PHx rat model of oval cell 
activation, Stat3 was highly upregulated in the oval cell population that corresponded with the 
highest proliferative potential [303]. This supports our finding that inhibition of Stat3 resulted in 
a proliferation defect in LPCs at R6h (Figure 37). Therefore, we can speculate that the smaller 
liver size at R24h is a result of the lower number of LPCs established at R6h, resulting in 
subsequent lower number of LPCs available for differentiation and expansion.  
Several mouse studies have also examined the role of Stat3 in liver regeneration. For 
example, following partial hepatectomy in liver-specific Stat3 conditional knockout (L- Stat3-/-) 
mice, the mortality rate was significantly increased during liver regeneration [304]. This increase 
was speculated to be due to a defect in the Stat3-dependent acute-phase response; this response is 
activated following liver injury and involves the induction of survival-related proteins [312, 313]. 
In a separate model of liver injury (i.e., CCl4), although liver-specific Stat3 knockout mice had 
slight decrease in DNA synthesis, they displayed no difference in survival or necrosis compared 
to wild-type littermates [304].  
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In our BEC-driven liver regeneration model, we discovered an absence of Bhmt staining 
in 75% of JSI-124-treated regenerating livers at R6h, which indicated a LPC-to-hepatocyte 
differentiation defect. However, at R24h, no difference was observed in Bhmt staining between 
DMSO-control and JSI-124-inhibited regenerating livers, indicating a delay in hepatocyte 
differentiation rather than a complete blockage. One explanation for the delay is that Stat3 is one 
of several proteins implicated in hepatocyte differentiation and upon Stat3 inhibition, other 
compensatory mechanisms are instead activated to counteract the deficiency. Such a phenomenon 
was detected in liver-specific Stat3 knockout mice, which displayed STAT1 activation in liver 
extracts compared to control mice [314].  
Depending on the cell type and injury-stimulus, Stat3 plays a critical role in several 
biological processes, including proliferation, apoptosis and inflammation. Previous studies have 
implicated Stat3 in the regulation of myogenic differentiation in skeletal muscle [315, 316]. Stat3 
activation in satellite cells during muscle repair drove these multipotent cells to choose 
differentiation over self-renewal, which predictably led to a smaller satellite cell pool. In contrast, 
ablation of Stat3 in satellite cells promoted the precursor, satellite cells to self-renew instead, 
leading to enhanced repair [317]. Similarly, in our liver regeneration studies, Stat3 inhibition also 
led to a transient hepatocyte differentiation defect, indicating that Stat3 regulates the decision of 
LPCs to either commit to a hepatocyte fate or proliferate. Although Stat3-inhibited livers displayed 
a proliferation defect, we did not observe any difference in cell death between JSI-treated and 
DMSO-treated regenerating livers.  
Although we did not address the upstream activators or downstream mediators of the Stat3 
signaling pathway, future studies can focus on identifying these factors and their role in LPC 
proliferation and differentiation. Factors such as the interleukin (IL) cytokines may be important 
 127 
activators of Stat3 pathway during BEC-driven liver regeneration. In particular, IL-6 treatment 
caused a decrease in the number of LPCs in CDE diet-fed mice [214]. Findings from current and 
future studies can provide insight into developing novel therapies for patients suffering from 
chronic liver diseases.  
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5.0  CONCLUDING REMARKS AND FUTURE DIRECTIONS 
Altogether, these findings establish the power of zebrafish in two ways: (1) in the study of liver 
development and (2) in using the complete hepatocyte-specific ablation injury model to reveal 
underlying mechanisms in LPC/BEC-driven liver regeneration. We have shown that Id2a, a HLH 
factor downstream of the BMP signaling pathway, is an important regulator of hepatic outgrowth 
during hepatogenesis. In fact, id2a knockdown results in a smaller liver during liver development. 
This failure of the liver bud to expand is caused by decreased hepatoblast proliferation and 
increased hepatoblast cell death during liver development.  
We also concluded that BMP signaling pathway is important for regulating LPC-to-
hepatocyte differentiation and BEC proliferation. BMP-deficient livers failed to establish mature 
hepatocytes after LPC induction and displayed increased number of BECs. These phenotypes were 
mediated by factors Tbx2b and Id2a, respectively.  
During liver development, the finding that Id2a knockdown resulted in a smaller liver size 
raised an important question about the type of bHLH factor that was negatively regulated by Id2a. 
As mentioned earlier, the main function of Id2a is to dimerize with bHLH (or ETS factors) and 
negatively regulate their activity by preventing them from binding DNA. Since the liver size was 
decreased after Id2a knockdown, we speculated the unknown bHLH factor to function as a 
repressor of hepatic outgrowth during liver development. To identify the potential bHLH factor, 
we conducted a literature search of bHLH factors that were either expressed in the liver or 
important in developmental processes. Next, from a narrowed list of 50 candidates, we completed 
an in situ analysis of bHLH factors during liver development, especially focusing on stages of 
hepatoblast specification and BEC differentiation. Findings from the in situ screen are presented 
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in Appendix B. Future studies can focus on knocking down bHLH factors specifically expressed 
in the hepatoblasts and BECs and examining effect on hepatic outgrowth. Finally, we can confirm 
the binding target of Id2a by conducting biochemical studies using Co-immunoprecipitation 
assay/Western blotting or the yeast-2-hybrid system. Since the id2a mutants also exhibit a transient 
BEC phenotype during BEC-driven liver regeneration, we speculate that Id2a binds a biliary-
specific bHLH factor that regulates BEC proliferation. Since during development Id2a is expressed 
in a subset of the BECs, future experiments can examine whether all proliferating BECs (EdU+) 
observed in regenerating livers are also Id2a-negative.  
In addition to the BMP signaling pathway, the Stat3 signaling pathway is also necessary 
for proper BEC-driven liver regeneration. By chemically inhibiting Stat3 via the JAK-specific 
inhibitor, JSI-124, we observed a reduced liver size and BEC number in regenerating livers. 
Additionally, the LPC-to-hepatocyte differentiation, which can begin as early as R6h, was delayed 
until R24h. Future studies can focus on elucidating the upstream activators and downstream 
mediators of Stat3 signaling pathway in BEC-driven liver regeneration. One approach to reveal 
the downstream factors is to conduct a qPCR analysis by dissecting livers from both DMSO- and 
JSI-124-treated larvae at R6h (for LPC proliferation and LPC-to-hepatocyte differentiation defect). 
Based on our liver regeneration phenotypes, we expect hepatocyte-specific genes (such as 
fabp10a, bhmt) and proliferation-related genes (cyclinD1, myc) to be downregulated in JSI-124-
treated livers. Additional, known downstream target genes of Stat3 can also be examined, such as 
socs3a, zip6, mcl-1a, mcl-1b, bax1 and bcl-2.  
 In addition to Stat3, previous studies have highlighted the cross-talk between Stat3 and 
NF-κB pathways (reviewed in [318]). Hence, we hypothesized that in addition to Stat3 signaling, 
NF-κB pathway was also important for BEC-driven liver regeneration. Using the Tg(6xHsa.NF-
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κB:eGFP) line [319], we showed NF-κB activation in the regenerating livers (see Appendix C; 
Figure 43). To elucidate the role of NF-κB in BEC-driven liver regeneration, future experiments 
can focus on finding a reliable method of blocking and/or enhancing NF-κB signaling in 
regenerating livers (see Appendix C; Figure 44).  
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APPENDIX A 
CHAPTER 3 TABLES 
Table 1: Transgenic and mutant lines used in Chapter 3 
Names used in this study Official names (ZFIN database) Allele # Ref 
Tg(Tp1:VenusPEST) Tg(EPV.Tp1-Mmu.Hbb:Venus-Mmu.Odc1) s940 [320] 
Tg(Tp1:H2B-mCherry) Tg(EPV.Tp1-Mmu.Hbb:hist2h2l-mCherry) s939 [320] 
Tg(ubb:loxP-GFP-loxP-mCherry) Tg(-3.5ubb:LOXP-EGFP-LOXP-mCherry) cz1701  [321] 
Tg(Tp1:CreERT2) Tg(EPV.Tp1-Mmu.Hbb:Cre-ERT2,cryaa:mCherry) s959 [322] 
Tg(fabp10a:CreERT2) Tg(fabp10a:Cre-ERT2,cryaa:ECFP) pt602  [20] 
Tg(fabp10a:rasGFP) Tg(-2.8fabp10a:CAAX-EGFP) s942 [323] 
Tg(fabp10a:CFP-NTR) Tg(fabp10a:CFP-NTR) s931  [20] 
Tg(hs:dnBmpr1) Tg(hsp70l:dnXla.Bmpr1a-GFP) w30 [324] 
Tg(Tp1:mAGFP-gmnn) Tg(EPV.Tp1-Mmu.Hbb:mAGFP-gmnn) s707 this study 
Tg(WRE:d2GFP) Tg(OTM:d2EGFP) kyu1 [325] 
smad5 smad5 m169 [273] 
tbx2b tbx2b c144 [276] 
id2a id2a pt661 this study 
 
Table 2: Sequences of primers used for in situ probe synthesis 
Gene Primer Nucleotide sequence (5' to 3') 
pprc1 forward CTAGCATTGTTATCAAGACCGTTG 
pprc1 reverse GCCTTTTTGTATCCTCACTGCTAT 
tfpia  forward CAGGTTTTACTTTGACATCGACAC 
tfpia  reverse TCTTTATCCGTATTTGCTTTCTCC 
hmgb3a forward GCTTATGCCTATTTCGTTCAGACT 
hmgb3a reverse CTATTCGTCGTCGTCATATTCGT 
hmgb2b forward GGTGAAAGGAGACGTGAACAA 
hmgb2b reverse TCTTCCTCATCATCTTCCTCGT 
hmgb2a forward GTAAAGATCCAAATAAGCCCAGAG 
hmgb2a reverse CTCATCATCGTCATCATCAGCTT 
cbx3a  forward CAGGCAAGTCAAAGAAGGAAGTT 
cbx3a  reverse GCTCATCCTCAGGACAAGAATG 
cbx5 forward ATGGGAAAGAAGAGCCAGAAC 
cbx5 reverse CTGTGGCACTCTTCTCCTTCTTG 
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brd3a  forward TTTCAACACAATGTTCACAAACTG 
brd3a  reverse TTGACAGCATTTCTTTAAGGATGA 
foxp4 forward CCAGCCGTAGAGTGAAAGTAGAGT 
foxp4 reverse GTAGATTCAGAATGTGTTGCTGCT 
foxp1a  forward TAAAACTCAGACTCTCAACCACCA 
foxp1a  reverse TGTTCGAGTGAACCAGTTGTAGAT 
tbx2b forward ATAAATATCAGCCCAGGTTCCATA 
tbx2b reverse GGAGAGAAGCTGTCTTTACTACCG 
id2a  forward TCCTGCTGTCAACATGAAGGCA 
id2a  reverse TAATACGACTCACTATAGGGCCAGTTCCCAGGTCCTGTGTGT 
mlf2 forward TTTCGTTACTTGAATGATGTGGAT 
mlf2 reverse ATAATCTAAACTGCGGGCAGTAGG 
irf6 forward AGTATCAGGAAGGAGTGGATGAAC 
irf6 reverse GAACAGCTCCTCTTGGTTCACTAT 
igf2a forward GGATGATTACCATGTATTCTGTGC 
igf2a reverse GTTTGCTCCTCATCTTGGATTTT 
akt2 forward ACAGCAATTCTGAAAGAGAGGAGT 
akt2 reverse GCCAAAGTCTGTGATTTTAATGTG 
sgk1 forward ACAAGATGTGGAGCTAATGAACAG 
sgk1 reverse GCAGGCCATATAACATTTCATACA 
plk3 forward GAATCCACCTTTTGAAACCTTAGA 
plk3 reverse AAGACAAGCAGCTGTTAAGAACCT 
mych forward GTATCTGAACTTTTAATGGAGGACAC 
mych reverse TAATACGACTCACTATAGGGATCTGCAGACCTCGCTGGGAGT 
max forward CAACGATGATATCG AGGTCGACAG 
max reverse TAATACGACTCACTATAGGGTGAAACAGGCCATTGCTGTGACTC 
mdm2 forward TACAGATTCAGACTCTCGCTCATC 
mdm2 reverse GAGTTTCTTTTCGAAGGTTGTGTT 
rbb4 forward AATCATGAAGGAGAGGTTAACAGG 
rbb4 reverse GAACCTGGAAGATTTCATCTTTGT 
rbb4l forward TGGATCAGTTAGTGGAAAGATTGA 
rbb4l reverse GACCTGGAAGATTTCATCCTTATG 
smad5 forward AAACAGAAAGAAGTGTGCATCAAC 
smad5 reverse ACCTCTCCTCCAACATAGTACAGG 
epcam forward CACAATGTGCTTGTAAAACAATGA 
epcam reverse TAGATCAGGACATTCTCCATTGAA 
mmp15b forward AGGTAATGATCTGTTCCTGGTAGC 
mmp15b reverse GAAGAAGTAAGTGAAGCCAGAAGG 
samd4 forward ACCTTCAAAGTGCCCTCGT 
samd4 reverse GTCTAACGGTGTGGGGTCTG 
smad1 forward AAGGCCCTAGAGTGCTGTGA 
smad1 reverse GGACTCCTTTTCCGATGTGA 
smad9 forward GCACAGCTTCCCAAACTCTC 
smad9 reverse CCGTGCAGGTGGATTTCTAT 
Underlined are T7 primer sequences. 
 133 
Table 3: Sequences of primers used for qPCR 
Gene Forward primer sequence (5' to 3') Reverse primer sequence (5' to 3') 
pprc1 TGCTACGGTTGAGCTGATTG AGGCAGTGGTCTTGCCTCTA 
tfpia CAAGGCAATGAAGGACAGGT TTGGCTTCCTCTTCCTCTGA 
hmgb3a TTGAAGACATGGCCAAACAA ACAGTTAGCCATTGGCATCC 
hmgb2b TATGCGTTCTTCGTGCAGAC TCTTTGCTGCTCTGCTTTGA 
hmgb2a CCTCTTACGCCTTCTTCGTG GGTGAAAGCTTGGACCACAT 
cbx3a AGGTAATGGACCAGCGAGTG CGCTTCATCAGAGTCCTTCC 
cbx5 AAGAAGAGCCAGAACCGTGA TTTTTCCTCTTGCTGGTGCT 
brd3a GGGTGCGGAACAGTGTATCT TTCTTTGGTTGCCTGTTTCC 
foxp4 GGTTTTCCTGAGGGTCTTCC CGTTGCTGTGTTTCTCCTGA 
foxp1a ACTGGCTCTCCTCTGGTGAA TTGGTGTCTGGACTCTGCTG 
tbx2b GCCAAAGGCTTCAGAGACAC TCGTCTTTCTTCTCCGCAAT 
id2a GAAGGCAATAAGCCCAGTGA GTCAGGGGTGTTCTGGATGT 
MLF2 ATGGATCCGTTTGCTCTCAC ATCGTTTGACGCGTCTCTCT 
irf6 GCTGGTCTGGCTGGATAGAG CCGTCTCGTATGTGGGAACT 
igf2a GACTCTCTGTGGCGGAGAAC GGTTTGCTCCTCATCTTGGA 
akt2 AGAACACACGGCATCCTTTC GTCTTCATGGTGGCCTCATT 
sgk1 GTGCTTTGGGTTACCTGCAT CTGCAGTGGCTTGTTCAAAA 
plk3 CCGGGAGGTCGTACTGTAAA GATGCCTTTGTTGTGGAGGT 
mych CTCCGACATAGACACGCAGA TGCTGCTGGATTTCAAAGTG 
max TCGAGGTCGACAGTGATGAA TTGGTGTACAGGCTGCTGTC 
mdm2 CCTCCTCTTCCTCGACACTG GGGTCTCTTCCTGACTGCTG 
rbb4 GTTCATTCTGGCCACAGGTT CCCATGGTTCATTTGGATTC 
rbb4l GTGTTGGGCACACACACTTC TTCCAGGACAAACCATAGCC 
smad5 CGGCTCCAAACAGAAAGAAG GTCTTGCCCCATCTGTTCAT 
epcam CTTGTTTGTTGTGGCATTGG TTGACGCACCAGCATACTTC 
mmp15b GAGCCGCAGATCAGGACTAC TCAGAACCACATCCACCTCA 
hnf4a GCCGACACTACAGAGCATCA TGGTAGGTTGAGGGATGGAG 
eef1b2 CCCTCTCAGGCTGATATTGC TAAGCTGCAAGCCTCTCCTC 
G6pc TCTGTCCCGGATCTACCTTG GAAAGTTTCAGCCACAGCAA 
Tdo2 GGGGATCCTCAGGCTATCAT AATCCACAAAAACCTTGTACCTG 
Tat GGAGGAGGTCGCTTCCTATT GCCACTCGTCAGAATGACATC 
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APPENDIX B 
CHAPTER 4 EXPERIMENTS 
To determine whether the Stat3 inhibitor phenotype would be recapitulated in the Stat3 
homozygous mutants, we obtained the stat+/- zebrafish mutants [310]. In the stat3-/- mutants, we 
examined three main phenotypes that we also observed in the JSI-124 treatment case: (1) LPC-to-
hepatocyte differentiation, as measured by Bhmt staining; (2) BEC number, as measured by 
Tp1:H2B-mCherry+ cells; and (3) proliferation defect, as measured by EdU staining. First, similar 
to the JSI-124-treated livers, the stat3-/- mutants also exhibited reduced Bhmt staining at R6h 
during BEC-driven liver regeneration (data not shown), indicative of an initial defect in LPC-to-
hepatocyte differentiation. This defect was observed in only about 20% of the stat3-/- mutants, 
possibly due to an incomplete penetrance of the homozygous mutant phenotype. Moreover, as in 
the JSI-124-treated livers, hepatocyte differentiation is not blocked, but rather delayed as Bhmt 
staining at R24h showed no difference between wild-type and stat3-/- mutants (Figure 39A). 
Second, the number of BECs were significantly decreased in the stat3-/- mutants; again, this BEC 
decrease was observed in a subset of the stat3-/- mutants and was not as robust as we observed in 
the JSI-124-treated regenerating livers (Figure 39A). Lastly, unlike the chemical inhibitor 
experiments, stat3-/- mutants displayed no significant difference in the percentage of EdU+ 
cells/Tp1:H2B-mCherry+ cells at R6h (Figure 39B). Although we cannot identify a proliferation 
defect as the reason for the decreased BEC number, we cannot rule out the possibility that the 
decreased number of BECs at R24h is instead due to the maintenance of LPCs in a progenitor cell-
like state. For future experiments, we will examine Hnf4a expression in Tp1:H2B-mCherry+ at 
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R6h and R24h in wild-type and stat3-/- mutants to determine if the lower BECs at R24h is caused 
by a retention of LPCs in their progenitor state.  
 In addition, we will also examine the socs3a-/- mutants closely to study the effect of Stat3 
hyperactivation on BEC-driven liver regeneration. Initial experiments at R6h indicated a delay in 
LPC-to-hepatocyte differentiation, although similar to the stat3-/- mutants, this phenotype was not 
fully penetrant (less than 20% of the homozygous mutants displayed the phenotype). Moreover, 
as in the stat3-/- mutants, no difference in Bhmt staining at R24h between wild-type and socs3a-/- 
mutants was observed (data not shown).  
 Lastly, because Stat3 has been implicated in cell survival and macrophage infiltration in 
other regeneration settings [326], we also sought to determine the role of Stat3 in macrophage 
recruitment in our BEC-driven liver regeneration model. Compared to DMSO-treated livers, Stat3-
inhibited livers had a significant increase in macrophage number during injury (A18h) and 
subsequent regeneration (R6h) (Figure 40). To determine whether Stat3 mediates its effect on 
BEC-driven liver regeneration through a macrophage-derived or -secreted factor(s), we can 
examine our liver injury model in irf8 zebrafish mutants which completely lack macrophages 
during embryogenesis and instead have an increased number of neutrophils [327].  
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Figure 39: stat3 homozygous mutants exhibit fewer BECs during BEC-driven liver regeneration 
(A) Confocal projection images revealing Tp1:H2B-mCherry (BECs; red) expression and Bhmt (gray) 
staining in R24h regenerating livers. Quantification of the number of H2B-mCherry+ cells as shown in 
(A). Scale bars: 20 µm; error bars: ±SEM. (B) Confocal projection images showing Tp1:H2B-mCherry 
(red) expression and EdU staining (gray) in regenerating livers at R6h. Quantification of the percent 
EdU+ cells per total number of BECs (H2B-mCherry+ cells) in the liver. Scale bars: 20 µm; error bars: 
±SEM.   
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Figure 40: Stat3 inhibition increases macrophage number in the regenerating livers 
(A) Confocal projection images revealing fabp10a:CFP-NTR (hepatocytes; blue), Tp1:H2B-mCherry 
(BECs; red) and mpeg1:dendra (macrophages; green) expression in A18h regenerating livers (n=8). 
Quantification of the number of dendra/mCherry double-positive cells in DMSO- and JSI-124-treated 
livers. Scale bars: 20 µm; error bars: ±SEM. (B) Confocal projection images revealing fabp10a:CFP-
NTR (hepatocytes; blue), Tp1:H2B-mCherry (BECs; red) and mpeg1:dendra (macrophages; green) 
expression in R6h regenerating livers (n=8). Quantification of the number of dendra/mCherry double-
positive cells in DMSO- and JSI-124-treated livers. Dotted lines outline the liver. Scale bars: 20 µm; 
error bars: ±SEM. 
 138 
APPENDIX C 
C.1 BHLH PROTEINS IN SITU SCREEN 
 
Figure 41: bHLH in situ screen to identify factors expressed in the liver during development 
Wild-type embryos (n=10 for each stage) were processed for WISH analysis with 50 bHLH probes at 36 
hpf and 72 hpf, after hepatoblast specification and differentiation stages, respectively. In addition, we 
also focused on bHLH factors specifically expressed in the liver BECs. 
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Table 4: Primer sequences for bHLH in situ probes 
Probe Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
   
her5 GCAAAAAGACATGAGAAGGGTCCC GCTTAGGACTTGAAGTCATGGC 
her12 CCTTTGACCATCTTCACTTCAGCG TGTTAATACCACCGTCCCTCAGG 
her11 GCACACCGACTTTCAACATGACG GCAGGATGTGCTGGTAAAAGTGG 
her1 CCGATTTTCAGCCATGGTTACTCC GGCTCTCATGTGTCCAATCGATTG 
her7 AACCTGAAACTTCTGCTCCTGC CCAAGGTCTCCAAACAGTCTGG 
her3 ATGGCTGCAGCATCCAACAG AGTCATTAGCCTACCAAGGTCGC 
her8a GGTCCGGAGAAGAATTTCAACGC AGAGCATGGGGCTGTAAGGAG 
her6 TGTATCAGCGTACTTGACAGCG CGGTGTTAACCCCTTCACATGTG 
her13 GTGGAGAAAAAGAGACGAGCACG GACCAGAAAACTCCAGTCCAGG 
her1 TAGAGAAGAAACGGAGAGACCG TGCAGGACAACTCTGGATTTGGG 
her8.2 AGCAGATGGACATGACTGCTACC TGGGCCTCTTACACAAGAAAGGAG 
her15.1 CACAAATTGCGAAAGCCAGTGG AGCACCATCTAGTGTTTGAGCG 
her9 GACAGCATCACCTATTGCTGGTG TCTGAAGGACTGAGTTTGGAACCC 
her2 CGCATCAACAAATGCATCGAGC GCAGAAACGTACTGAGGTGCC 
helt ATGCGCGAGCACTTTATAAGCG GGGTCTGGTGAGATTGTGCCTAA 
tfe3a GTCAATCTCATCAGCGTTGAGCC CGATCTCTTCTTTGTTGGACCCC 
tfe3b TGCAAACCCATCTGGAAAACCC TCTCCTTCATGAAAGCTCTGGCC 
tfeb ATTACATGCAGCATCGCATGCC CCTTCTCCTCCTTTCAATCAGG 
tcf25 CTGATAGGAGAGGCTGATGTGG TGGGTTGATCTGTAGGAGAACCAC 
tcf12 GGGCAGCATGTATTACTACAACGG GTTTGAGGGGAAACTACTGCTGG 
tfap4 ATGGTACCAGCTCAGAAGGTGC GAGCGCTCTTTATCCAGCTGC 
tcf21 TTTCACGAATCTGAGCTGCTGG TGAGTCTCAGGAAGCTGTAGTCC 
tcf24 GGTTGGAAGACAGTCGATCCG ACAGGATGTAAGTAGCCATCGC 
tcf20 GTTGATGGCCCTTTAAACACCC CTGGCTATAGCATTCTGGAAAGGC 
tfec ATCTGGAGAACTCCAAGTACCACC TGTTCCCAGCTCCTTGATCCTG 
tcf3a TCAAACGGGAAAAGCAGAGGC CAGACTGACCCCAATGATCTGG 
tcf3b GTGACCTGTTGGATTTCAGTGC TACACAGAGCCAGGTTTGGAG 
bhlhe23 CTGAAATCGATCAGCAACGACACC CGGAGAACGAGTTGCATTTCTCC 
bhlha15 CAGACTTTACGCTGGAAACAGAGC GTGCAGTGTGTGTTAGCTGTCC 
bhlhe22 GACTGCGGGTATTGATCTTTCCG TGCTCGTATGCGCTTAAACCC 
bhlhe40 GACATGCAAGGAATGGACTTTCCC GTCCTTTGAATGACAGGCACACAG 
bhlha9 ATATCCATGACTCCAGCGAGCG CCCAACATCACCAATCCGTCCATA 
srebf1 GCCCTTCTCAATGACATCGACG GAGTCGGCCTTAATGAACTGCG 
srebf2 GAGTTTATGGACACCATGGACCC TGCGGAGACGTCATGATACTCTG 
usf1 GTTCCAGTCATTGAAGAAGGGGC GCTCAACTTCATTGTGCTGAGC 
usf1l GGGTTCTGATCCTGAAGATTCTCC CCATTGGTTGATCTTGTCCCTCC 
usf2 CTCGATCAGAGCTTGGACACC TGTGTACGAGGAGCAATGGTCC 
nhlh2 GGCAAGATAACATCCAGTGCAC CTGTGCGTTTTCGATTTGATCG 
tal2 CAGGAAGGTGTTCACTAACACACG CCTGCAGTGTCTTGCCTTGATAC 
ahrrb TGTCTGTATGCTGGGAGAAAGAGG GTCACAACATCCTCATCAGTGTCC 
epas1b GCAGACGGAGTAAAGAGACAGAGG CCGTTACACACCTTTAGATGACCC 
hif1ab AGGTGTTCTACGAGTTAGCACACC GGCTCACAGATGAGCACAAGGTA 
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Note: T7 primer sequence was included in all reverse primers  
(5’-3’: TAATACGACTCACTATAGGG) 
 
hif1aa TTATGAGCTGTCCAGAGAACTCCC CCTTCTCAACACCATCTGCTGT 
ebf3 GGAACCACTATGAAAGAGGAACCG CGTCTCGTTCCTGTTTCCACAG 
ahrra GAGGAAGCCCATACAGAAGCAG CCCTGGAACTGCATAGTCAGGAA 
ahr1a GCAAAAGGAGGAAACCTGTCCAG GGACTGTAGCACGTCCTTGATG 
ahr2 CAGAAAATACCCAAACCACCACCC CCTGGTGATATCACTGCTGCTCT 
arntl1a AGCTCTGCAGATCTGATCAGCAG CCAGTTTTGGCATCGATGAGTCTC 
arntl1b GATCGTGTCAGAAAGCCTCAGG GCTCATCGTCTGATAAAAAGGCCG 
arntl2 AAACACAGGAGATGTGCTGGAG GTCCAATTAACTCCGTCCGACTGT 
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C.2 IN SITU SCREEN TO IDENTIFY GENES IMPORTANT IN BEC-DRIVEN 
LIVER REGENERATION 
 
Figure 42: An in situ screen of factors involved in the inflammatory signaling pathways 
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5 dpf embryos treated with DMSO (Control) or ablated with Mtz and examined at R6h (R6h) processed 
for WISH analysis (n=10 for each stage/condition). In total, 24 probes were used. Zebrafish mutants of 
il11ra, ftr82, ifrd1, ilf3a and ilf2 were obtained. None of these zebrafish mutants displayed any 
significant phenotype in our LPC/BEC-driven liver regeneration model.  
 
Table 5: Primer sequences for R6h in situ probes in BEC-driven liver regeneration 
Note: T7 primer sequence was included in all reverse primers  
(5’-3’: TAATACGACTCACTATAGGG). The plasmids for cxcr7b and cxcr12a were provided 
by Tatjana Piotrowski. The gp130 (il6st) plasmid was provided by Dan Goldman. The il11a probe 
was provided by Ken Poss. 
 
Probe Forward Primer Reverse Primer 
   
ilf2 TACGCAATGAGAGGAGATCGTG GCTTCCAAGGTGGGCAGAATCTT 
ilf3b AACACTCGGCCATCTATCCC GGTGAAGTCAGGTGAATGGTGA 
ilf3a AATCTCATGCAGGAGGGGTACC GGTGAGCAGCACCAACTCTAA 
il13ra AAGCATGTCAGAGCTTCCTC TGAAGATGGGAGGATGTGTC 
crfb5 AACACCCAGTATGTGCTGCAC GCTCTTTAGCCTGCCGAGTGT 
irf2bp2b TTTCAGGAGGGCAGATCACC CCCTTCTGCGTCCACTCAT 
il11ra ATCCTCTTCTGTGAGCTCGTCAC CGGTATCCTTCTGTTCACAGGGTT 
fosl1a AAGTACTCTGTGGCAGGATCAGG GTCAGTTCTCGTCGACGGTTCCTA 
socs3a AAGACCTTCAGCTCCAAGGTG GTGTGTCCGTTCACAGTCTTCCT 
egr2a TACTCGGCCCCAAAATCAACC CATGCAGATGCGGCACTGAAA 
csrp1a TCATATCCACACACCTAGCAGG GCACATTGCACATCGGAA 
ifrd1 AACAGGGAAATGTCCAACCG CGCAAGCTTGTCTGGCTTGAA 
nfkiab ATTGCTCTCAAACACCGACGAG CCTTGTGTTAGGAGGCCGAA 
ftr82 ATGGCTGAGCAAATGTCTCCAG CTGACAGTACAGATGGCGCAA 
ets2 ATGGAGTCGCTTTTACCTGG CAGCTGCAGTCAGACACCTT 
icn ATCGTGACCACCAGAACCACC CTCCTGAAAGTCCACAGAACCA 
csrnp1b TACTCAGAGTGGGACTCAGATGG GGAAGGAGCCATCATCCACATT 
nfil3 AAAGAGCCCCCATGCAGTGG GGTGAGTGCTTGATGACCGAA 
il6r AATGTGTCGTTGGCTTCAGC GCATGCACCTGTCTTCCAT 
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C.3 NF-ΚB IN BEC-DRIVEN LIVER REGENERATION 
C.3.1 NF-κB Expression in BEC-driven Liver Regeneration 
 
Figure 43: Expression of active NF-κB signaling in the liver during BEC-driven liver regeneration 
(A) Scheme illustrating Mtz treatment (A, ablation) and liver regeneration (R, regeneration). (B) 
Confocal projection images revealing fabp10a:CFP-NTR (hepatocytes; blue), Tp1:H2B-mCherry 
(BECs; red) and 6xHsa.NF-κB:eGFP (green) expression in non-ablated control embryos and at different 
stages of liver regeneration (R6h, R24h, R48h). NF-κB appears to be expressed in a subset of mCherry+ 
cells during regeneration. In control embryos, NF-κB is mostly absent, only appearing in 1-2 endothelial 
cells (data not shown). At later stages, it appears to be maintained in mature BECs.  
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C.3.2 Inhibiting NF-κB in BEC-driven Liver Regeneration 
 
 
Figure 44: Inhibiting NF-κB signaling in zebrafish larvae during development 
(A) Scheme illustrating the NF-κB inhibitor, JSH-23, treatment in non-injured, developing larvae. (B) 
Epifluorescence images of 6xHsa.NF-κB:eGFP (green) expression at 48 hpf or 72 hpf in NF-κB-
inhibited larvae. For 48 hpf and 72 hpf embryos, 400 M JSH-23 was administered for either 18 hours 
(from 30 hpf to 48 hpf) or 24 hours (from 48 hpf to 72 hpf), respectively. Following washout, embryos 
were anesthetized and mounted in 3% methylcellulose for imaging. No difference in GFP activity was 
observed in either case. A better method of NF-κB inhibition is needed for further study.  
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